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"Schau tief in die Natur, und dann wirst du alles besser verstehen."  
Albert Einstein (1879-1955) 
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Abstract 
 
Global warming together with the extensive agriculture favours the uncontrolled 
growth of cyanobacteria, also called blue-green algae. Being one of the oldest life 
forms on our planet, they have reached evolutionary perfection over time. They are 
distributed at a variety of habitats, primarily in water. Cyanobacterial blooms present 
immediate danger to animals and humans, as cyanobacteria are known to produce 
various toxic compounds. This thesis addresses some of the open questions 
regarding cyanobacterial toxins. The current project involves the isolation, 
characterization, derivatization and biological and toxicological evaluation of various 
toxic compounds derived from cyanobacteria. 
 
 
 
 
 
 
 
 
Figure 1. Cyanobacterial culture 
 
Our attempts for labelling cyanobacterial toxins led to the development of an 
optimized protocol for arginine derivatization in complex peptides. This 
straightforward procedure allows modifying the arginine moiety in peptides containing 
with other functional groups, such as fluorophores or biotin under mild conditions in 
an operatively simple procedure. This method was applied for labelling leuprolide, a 
clinical drug, for in vivo studies in Daphnia. 
 
 
 
 
 
 
Scheme 1. Arginine derivatization strategy 
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Microcystins are one of the most common and widely distributed cyanobacterial 
toxins. Their hepatotoxicity in humans makes them an important compound class. 
Microcystin-LR is the most toxic and common representative of the microcystin family 
(LD50 = 50 !gkg-1), yet the precise mechanism of its action is still under debate. To 
gain an insight into the uptake, distribution, accumulation and excretion of MC-LR, 
biological studies are necessary. One way to investigate the molecular mechanism of 
interaction of microcystin-LR is fluorescence labelling. An efficient synthesis route for 
the modification of the toxin’s arginine-residue was established, which allowed the 
preparation of microcystin derivatives with a variety of markers attached (fluorescent 
tags, biotin, diazirine). These derivatives preserved the parent toxicity as judged by 
phosphatase inhibition assays, cell viability assays, and acute toxicity assays against 
Thamnocephalus platyurus. 
 
 
 
 
 
 
 
 
Figure 2. Microcystin derivative 
 
Structure elucidation of a newly isolated toxic peptide,aeruginosin 828A, from 
Planktothrix strains was conducted. 2D-NMR studies and MS-characterization of the 
toxin revealed the presence of phenyllactic acid (Pla), chloroleucine (Cleu), 
2-carboxy-6-(4’-sulfo-xylosyl)-octahydroindole (Choi), and 3-aminoethyl-1-N-
amidino-"3-pyrroline (Aeap) residues. This peptide showed inhibitory activity against 
thrombin and trypsin. Furthermore, for the first time within this compound class, 
toxicity against Thamnocephalus platyurus was observed. This toxic peptide could 
only be found in microcystin-deficient Planktothrix strains.  
 
 
 
 
Label
OMe
O
HN
COOH
O
N
O
NH
HN
O
H
N
O
H
N
NH
O
HN
COOH
O
H
HN NH
!!
Abstract 
!
! !
9 
 
 
 
 
 
 
 
Figure 3. Aeruginosin 828A 
 
Another group of toxins, produced along with the microcystins via the nonribosomal 
pathway, are the cyanopeptolins. A member of this group, cyanopeptolin 1020, is a 
potent inhibitor of trypsin, human kallikrein and factor Xia. Unlike the microcystins, 
cyanopeptolins and cyanopeptolin 1020 in particular have not been investigated in 
detail so far. One way to get a better understanding of the toxicity of this compound 
class are biological test with fluorescently-labelled cyanopeptolins. A method for 
labelling the glutamate residue in cyanopeptolin 1020 was established. The protocol 
allows fast coupling on the carboxylic function of the toxin. As the products are highly 
sensitive, an improvement for product stability is under investigation.  
 
 
 
 
 
 
 
 
 
Figure 4. Cyanopeptolin 1020 
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Zusammenfassung 
 
Steigende globale Durchschnittstemperaturen in Verbindung mit extensiver 
Landwirtschaft begünstigen das unkontrollierte Wachstum von Cyanobakterien, 
früher bekannt als Blaualgen. Da diese zu den ältesten Lebensformen auf der Erde 
zählen, sind sie in ihrer Lebensweise perfektioniert. Sie besiedeln viele verschiedene 
Ökosysteme, hauptsächlich jedoch Wasser. Unglücklicherweise produzieren diese 
Organismen eine Reihe verschiedener Toxine, weswegen von einer Algenblüte unter 
Umständen große Gefahren für Mensch und Tier ausgehen können. Diese Arbeit 
behandelt offene Fragestellungen zu cyanobakteriellen Toxinen. Die Projekte 
umfassen die Isolation, die Charakterisierung, die Derivatisierung und die biologische 
sowie toxikologische Analyse von verschiedenen Verbindungen aus Cyanobakterien.  
 
 
 
 
 
 
 
Abbildung 1. Cyanobakterien-Kultur  
 
In Hinblick auf die Markierung von Cyanotoxinen wurde eine effektive 
Derivatisierungsmethode für Arginin in komplexen Peptiden etabliert. Dieses 
unkomplizierte Verfahren erlaubt eine unter milden Bedingungen durchführbare 
Modifizierung der Arginin-Funktion in Peptiden mit verschiedenen funktionellen 
Gruppen, wie zum Beispiel Fluorophoren und Biotin. Diese Methode wurde auch für 
die Markierung des Medikaments Leuprorelin angewandt, um anschließend in vivo 
Studien in Daphnien durchzuführen.  
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Schema 1. Strategie zur Arginin Derivatisierung 
 
Microcystine gehören zu den häufigsten und verbreitetsten cyanobakteriellen 
Toxinen. Durch ihre Hepatotoxizität gehören sie zu einer bedeuteten Stoffklasse. Der 
häufigste und am stärksten toxisch wirkende Vertreter aus der Klasse der 
Microcystine ist Microcystin-LR mit einem LD50-Wert von 50 !g kg-1. Jedoch ist die 
genaue Ursache für diese starke Toxizität noch völlig unbekannt. Um die Aufnahme, 
die Verteilung, die Akkumulation und die Ausscheidung von Microcystin-LR im 
Organismus zu verstehen, sind biologische Studien unerlässlich. Eine zentrale 
Methode um die molekularen und zellulären Mechanismen zu untersuchen, ist die 
Verwendung fluoreszenzmarkierter Derivate. Aus diesem Grund wurde im Rahmen 
dieser Doktorarbeit eine effiziente Synthese entwickelt, welche es erlaubt, 
verschiedene funktionelle Gruppen an die Arginin-Funktion von Microcystin-LR zu 
koppeln (Fluorophore, Biotin, Diazirin). Es wurde zudem gezeigt, dass diese 
Verbindungen in Inhibierungsassays, Zellviabilitätsassays und Toxizitätsassays mit 
Thamnocephalus platyurus vergleichbare Aktivitäten wie Microcystin-LR aufwiesen. 
 
 
 
 
 
 
 
 
Abbildung 2. Markiertes Microcystin  
 
Es wurde eine Strukturaufklärung eines neu-isolierten toxischen Peptids, Aeruginosin 
828A, aus sechs verschiedenen Planktothrix-Stämmen durchgeführt. Durch 2D-NMR 
Studien und massenspektrometrische Methoden konnten wir dessen Struktur 
N
H
H
N
O
HN
H2N NH2
+ X
O
Label
R2 N
H
H
N
O
R1
HN
HN NH
R2
OLabel
base
R1
Label
OMe
O
HN
COOH
O
N
O
NH
HN
O
H
N
O
H
N
NH
O
HN
COOH
O
H
HN NH
!!
Zusammenfassung 
!
! !
13 
aufgeklären. Folgende Fragmente wurden identifiziert: Phenylessigsäure (Pla), 
Chloroleucin (Cleu), 2-Carboxy-6-(4’-sulfo-xylosyl)-octahydroindol (Choi), und 
3-Aminoethyl-1-N-amidino-"3-pyrrolin (Aeap). Dieses Peptid inhibierte die Enzyme 
Thrombin und Trypsin. Zusätzlich wurde zum ersten Mal in dieser Verbindungsklasse 
Toxizität für Thamnocephalus platyurus beobachtet. Dieses Toxin wurde nur in 
Stämmen gefunden, welche nicht in der Lage waren Microcystin zu produzieren. 
 
 
 
 
 
 
 
Abbildung 3. Aeruginosin 828A 
 
Eine andere Gruppe von Toxinen, welche zusammen mit den Microcystinen durch 
nichtribosomale Peptidsynthese hergestellt werden, sind die Cyanopeptoline. Ein 
Vertreter dieser Klasse ist das Cyanopeptolin 1020, welches ein starker Inhibitor von 
Trypsin, Kallikrein und Faktor Xia ist. Im Gegensatz zu den Microcystinen wurden die 
Cyanopeptoline und das Cyanopeptolin 1020 bisher nicht ausführlich untersucht. Um 
die Toxizität dieser Verbindungen zu verstehen, ist es wichtig biologische Tests mit 
fluoreszenzmarkierten Cyanopeptolinen durchzuführen. Aus diesem Grund haben wir 
eine Derivatisierungsmethode für Cyanopeptolin 1020 am Glutamat-Rest entwickelt. 
Diese Methode ermöglicht eine schnelle Kupplung verschiedener funktioneller 
Gruppen an die Carbonsäurefunktion. Auf Grund hoher Sensitivität der 
Kupplungsprodukte, wird eine Verbesserung der Produktstabilität untersucht.  
 
 
 
 
 
 
 
 
 
Abbildung 4. Cyanopeptolin 1020 
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Abbreviations 
 
ACE inhibitor  Angiotensin-converting-enzyme inhibitor 
AcOH    Actid acid 
Adda 3-Amino-9-methoxy-2,6,8-trimenthyl-10-phenyl-4,6-
decadienoic acid 
Aeap     3-Aminoethyl-1-N-amidino-"3-pyrroline 
Ahp     3-Amino-6-hydroxy-2-piperidone  
Arg    Arginine 
Asx    Asparagine or aspartic acid 
BC     Before Christ 
BiP    Binding immunoglobulin protein 
Boc    Di-t-butyl dicarbonate 
BSA    Bis(trimethylsilyl)acetamide 
SPE    Solid-phase extraction 
Choi    2-Carboxy-6-hydroxyoctahydroindole  
CIE    International commission on illumination 
Cleu    Chloroleucine 
CP    Cyanopeptolin 
CP1020   Cyanopeptolin 1020  
CYP450   Cytochrome P450 
Cys    Cysteine 
D -Glu    D-Glutamate 
D-MeAsp   D-3-Methylaspartic acid  
DBU    1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCC    N,N'-Dicyclohexylcarbodiimide 
Dha    Dehydroalanine 
DiFMUP   6,8-Difluoro-4-methylumbelliferyl phosphate  
DMAP   4-Dimethylaminopyridine 
DMEM   Dulbecco's Modified Eagle's medium 
DMF    Dimethylformamide 
DMSO   Dimethyl sulfoxide 
DNA    Deoxyribonucleic acid 
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DTT    Dithiothreitol 
EDC    1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EGTA Ethylene glycol-bis(2-aminoethylether)-N,N,N#,N#-
tetraacetic acid 
ER-stress   Endoplasmic reticulum stress 
ESI    Electrospray ionization 
Et2O    Diethyl ether 
5(6)-FAM   5(6)-Carboxyfluorescein 
FBS    Fetal bovine sera 
Fmoc    Fluorenylmethyloxycarbonyl chloride 
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
Glu    Glutamate 
Glx    Glutamic acid or glutamine 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] 
pyridinium 3-oxid hexafluorophosphate 
His    Histidine 
HIV    Human immunodeficiency virus  
Hpla    Hydroxyphenyl-lactic acid 
HPLC    High-performance liquid chromatography 
HRMS   High-resolution mass spectrometry 
Huh 7 cells   Hepato cellular carcinoma cells 
Ile    Isoleucine 
L-Arg     L-Arginine 
LC-MS   Liquid chromatography–mass spectrometry 
LD50    Median lethal dose 
Leu    Leucine 
Lys    Lysine 
MC    Microcystin 
MC-LR   Microcystin-(Leucine-Arginine) 
Mdha    N-Methyldehydroalanine 
MeAsp   3-Methylaspartic acid 
MeCN    Acetonitrile 
MeDhb   Methyldehydrobutyrine 
MS    Mass spectrometry 
!!
Abbreviations 
!
! !
21 
MTT 3-(4,5-Dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium 
bromide 
N-Me-Tyr   N-Methyl-L-tyrosine 
NCS    N-Chlorosuccinimide 
NEt3    Triethylamine 
NHS-diazirine  Succinimidyl 4,4-azipentanoate 
NMM    4-Methylmorpholine 
NRPS    Nonribosomal peptide synthetases  
OATP    Organic anion polypeptide transporter  
pGlu     Pyrrolidone carboxylic acid 
Phe    Phenylalanine 
pKa    Ionisation constant 
Pla     Lactic acid  
PP2A    Protein phosphatase 2A 
qPCR    Quantitative polymerase chain reaction 
RNA    Ribonucleic acid 
RP-HPLC   Reversed phase high-performance liquid chromatography 
Ser    Serine 
TBTU O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
tetrafluoroborate 
TFA     Trifluoroacetic acid 
THF    Tetrahydrofuran 
Thr    Threonine 
TLC    Thin-layer chromatography 
Tris-HCl   Tris-(hydroxymethyl)-aminomethane-hydrochloric acid 
Trp    Tryptophan 
Tyr    Tyrosine 
UV    Ultraviolet 
Val    Valine 
WHO    World health organization 
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1.1 Natural products 
 
Natural products are compounds that originate from natural sources such as plants, 
microorganisms or animals. Among them, substances which have no primary role in 
the metabolism of the respective organism are referred to as secondary 
metabolites.[1] Because of evolutionary reasons, for example to give a species an 
advantage over another, many naturally produced compounds have an unique 
structure and thereby might act in various modes and to several different species.[2] 
Therefore these molecules also quite often interact with human proteins (e.g. 
teprotide a ACE inhibitor or muscarine a agonist of the muscarinic acetylcholine 
receptor), causing diverse positive or negative effects.[3,4] As a consequence, 
numerous compounds derived from plants, animals, marine- or microorganisms have 
been a source and inspiration for molecules with different purposes for human 
health.[5]  
The use of natural material as treatment for human diseases is very old, 
whereby even the Neanderthals might have utilized plants as origin for medical 
applications.[6] Furthermore, ancient civilisations, such as the Chinese, Indian, African 
and Greeks, used natural compounds to heal various sicknesses.[7] For example in 
India the medical curcumin was administered against eye infections and various skin 
diseases; Guggul from Commiphor wightii was used to treat different afflictions 
including internal tumors.[8,9] Nowadays herbal medicines are still in use in developing 
countries even serious diseases like malaria or tuberculosis are mainly treated by 
traditional medicine (Figure 1.1).[10]  
 
 
 
 
 
 
 
 
 
Figure 1.1. Bags of herbal medicine at a market in the town of Maradi 
Used with permission by © UNICEF/NYHQ2007-2652/Pirozzi       
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Until the nineteenth century, standardization of the herbal medicines was 
problematic due to varying concentration of the active compound and either the 
presence of toxic or harmful components in the plant material. This dangerous 
circumstance dramatically changed when Friedrich Wilhelm Sertüner isolated the 
pure, active compound morphine 1806 from Papaver somniferum.[11] With this 
academic achievement, it was possible to apply accurate doses of the 
pharmacological active substance to minimize side effects and intoxication. Since 
then numerous natural sources have been screened for relevant molecules to treat 
various diseases and is today a main source of new medicines, whereas an 
estimation indicates that 60 % of all available drugs come directly or in a derivatized 
form from natural products.[12,13] Besides morphine, aspirin from salicyclic acid in the 
willow bark (Salix), penicillin from mold (Penicillium) and the potent anticancer 
reagent taxol from the bark of the pacific yew tree (Taxus brevifolia) are very well 
known examples of powerful drugs having their origin in nature.[14-16] Furthermore, 
natural products may have the potential to cure yet undefeated diseases, which are a 
dominant issue in our society, such as cancer, HIV and neurodegenerative 
diseases.[17-19] Additionally they can be a powerful tool against the significantly 
growing problem of multidrug resistant strains of bacteria, for example in 
M. tuberculosis.[20] 
The positive health effect aside, the natural products can also act as toxins 
and cause serious poisonings. Many plants and animals contain potent toxic 
compounds mainly used as defence against predators or to hunt a prey. Some of the 
most potent toxins on our planet are derived from natural sources for example the 
deadliest plant poison ricin, originated from the castor bean (Ricinus communis), or 
the most potent toxin existing on earth, produced by the bacterium Clostridium 
botulinum.[21,22] In the past, poisonous substances obtained from natural sources 
were often used for intentional intoxication. As an example the alkaloid atropine from 
Atropa belladonna has been used by women for dilating the pupils but also for 
homicide.[23] Another example is the alkaloid strychnine from Strychnos nux vomica, 
which was the prevailing toxic compound to kill people with poisoned chocolate.[24,25] 
One of the most prominent cases of death through poisoning with natural products is 
the execution of Socrates in 399 BC with hemlock.[26] More often, though, intoxication 
happens as an accident by unwilling consumption or accidental contamination with 
toxic compounds from natural sources.[27-29] To protect humans from these naturally 
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occurring toxins, to find antidotes or treatments for acute intoxication, it is crucial to 
study certain toxins in more detail to understand their origin and mechanism of 
action.
!!
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1.2 Cyanobacteria 
 
Cyanobacteria (formerly called blue-green algae) are one of the oldest species on 
our planet, as indicated by fossils findings from western Australia, which postulate an 
existence on Earth for 3.5 billion years.[30] For this reason, cyanobacteria can be 
found almost everywhere, whereby the majority lives in water (freshwater, brackish 
water as well as saline water).[31]  
Furthermore, they can grow on terrestrial habitats and in soil, where they manage to 
survive on surfaces of buildings, on rocks, in mountains and on tree bark.[32] In 
addition, cyanobacteria can adapt and survive environmental stress, such as dry 
periods, very high and low temperatures, as well as large temperature amplitudes. 
They can inhabit Polar Regions, Antarctic terrestrial environment or hot springs (e.g., 
at the Yellowstone National park at 74 °C).[33-37] Even extreme hostile environments 
like volcanic ash and desert sand are occupied by cyanobacteria.[38,39] Some species 
like Synechococcus/Synechocytsis spp. can live in symbiosis with dinoflagellates, 
whereby others associate with fungi and plants.[40-42] 
This synergy is mainly due to the ability of cyanobacteria to fix nitrogen from 
the atmosphere, which is then further enzymatically converted into ammonia.[43,44] 
Responsible for this process are specialised cells, the so-called heterocysts, which 
are large and round shaped and possess thick cell walls with oxygen-binding 
glycolipids, necessary for nitrogen fixation under anaerobic conditions.[45] As energy 
source, these photoautotrophic organisms use photosynthesis.[46] This circumstance 
and likewise the age of cyanobacteria are assumed to have played a key role in the 
evolution of life on Earth as this species may actually have generated the first oxygen 
in the atmosphere.[47]  
Cyanobacteria are unicellular or multicellular prokaryotes, which belong to the 
Bacteria domain, whereby the multicellular bacteria can be further categorized in 
filamentous, undifferentiated and differentiated species.[48,49] The multicellular 
bacteria are able to communicate intercellularly, differentiate and form colonies 
(cell-cell adhesion).[50] An example for an unicellular bacteria is Microcystis 
aeruginosa. An example of multicellular filamentous and undifferentiated bacteria is 
Planktothrix. Anabaena sp. belongs to the group of multicellular differentiated 
cyanobacteria (Figure 1.2).[51]  
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Figure 1.2. A: Microcystis aeruginosa; Used with permission by Bettina Eugster & Esther 
Kohler B: Planktothrix rubescens; Used with permission by Thomas Posch C: Nostoc sp. 
 
Cyanobacteria produce a great variety of secondary metabolites, such as 
carotenoids, fatty acids, lipopetides, polysaccharides, as well as different bioactive 
molecules.[52] A large number of the cyanobacterial compounds are peptides or 
contain a peptide-like substructure. So far more than 600 representatives have been 
characterized.[53] These compounds are not only structurally diverse, but they also 
contain a number of unusual or modified amino acids. 
As cyanobacteria have populated the Earth for a long time, it is not surprising 
that many of the above-mentioned molecules show significant bioactivity. It has been 
reported that some secondary metabolites of cyanobacteria show anticancer, 
cytotoxic, antibiotic, antifungal and antiviral activity, as well as have antimycotic, 
immunosuppressive and anti-malarial features; additionally, they even show activity 
against multi-drug resistant bacteria.[54] As the compounds, produced by 
cyanobacteria, are chemically stable and with good water solubility, they can be 
considered as promising candidates for medical applications, such as the anticancer 
agent dolastatin, whereby its synthetic analogue soblidotin has entered phase III of 
clinical trials.[55,56]  
In addition to these compounds that may have a positive impact by being 
potentially used as drugs, cyanobacteria produce several highly toxic molecules, the 
A 
B 
C 
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cyanotoxins, which pose a danger to humans, animals and the ecosystems as a 
whole.[57] These toxins are also characterized by a high chemical stability and water 
solubility and thereby have the potential to cause severe intoxication in humans and 
animals.[57] In fact, due to eutrophication, cyanobacteria often grow uncontrollably in 
aquatic environment and cause dangerous blooms all over the world. In addition, 
climate changes and the rising temperatures on our planet could further facilitate the 
growth of toxic cyanobacteria so that they become an even greater problem.[45,58] 
Toxic blooms mainly affect warm regions as Africa or South America, where every 
year many people are affected and the fresh-water supplies are endangered.[59] 
Europe is also struggling with those problems, for example the Baltic Sea, where the 
occurrence of blooms increased over the past years. Furthermore, the lakes in 
Europe are also affected by increasing density of toxic cyanobacteria.[60-62] These 
phenomena of widespread cyanobacteria blooms are even visible from space, as a 
satellite picture clearly demonstrates (Figure 1.3).  
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Phytoplankton bloom in the Baltic Sea 
Used with permission by European Space Agency, ESA 
 
Over the past years, many cases of poisoning by cyanobacteria were 
reported, whereby the regular intoxication occurs via oral intake, although other 
uptake mechanisms, such as inhalation or skin contact are also possible.[63] The 
majority of the cases of intoxication occur in animals, for example at a lake in Canada 
where approximately 1000 bats died after ingesting contaminated water.[64] Humans 
also suffer from cyanobacterial poisoning. A tragic accident of acute intoxication with 
cyanobacteria containing water occurred in Brazil in 1996, where dialysis patients 
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were treated with contaminated water and this conjuncture lead to the death of 52 
people.[65] A more recent case of intoxication is reported in Argentina, where of a 
young person dived in a lake with a cyanobacteria bloom and afterwards suffered of 
clear intoxication symptoms (nausea and respiratory distress).[66]  
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1. 3 Cyanobacterial toxins 
 
Cyanobacteria produce a wide range of potent toxins, which structural variety comes 
from peptides, linear or heterocyclic, and lipid compounds (Figure 1.4).[67]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. A: Microcystin-LR; B: Anatoxin-a; C: Anatoxin-a(s); D: Saxitoxin; E: Nodularin; F: 
Cylindrospermopsin; G: !-N-methylamino-L-alanine 
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Based on their toxicity effect and their mode of action and uptake, the cyanobacterial 
toxins can be categorized into different groups; neurotoxins, cytotoxins, 
dermatotoxins, irritants and hepatotoxins.[68]  
For example, the neurotoxic compounds anatoxin-a, anatoxin-a(s) and 
saxitoxin are among the cyanobacterial toxins the most toxic compounds produced 
mainly by Anabaena, but display, due to their rare occurrence and therefore reduced 
exposure, a minor danger to humans when compared to the hepatotoxins, such as 
the microcystins (MCs) and nodularins.[69] Anatoxin-a is a bicyclic, secondary amine, 
which is a strong agonist of the nicotinic acetylcholine receptors.[70] Toxicity 
symptoms appear quickly after ingestion of contaminated water: paralysis, tremors, 
convulsions and death.[71]  
Anatoxin-a(s) constitutes an organophosphate, structurally not related to 
anatoxin-a, which irreversibly blocks acetylcholinesterase and enhances 
salivation.[72,73] Furthermore, the administration of pure toxin to mice leads to fast 
death and respiratory failure within a few hours.[74] Saxitoxin, produced by a 
freshwater cyanobacteria as well as marine dinoflagellates, is a strong neurotoxin, 
which accumulates in the food chain and causes paralytic shellfish poisoning.[75] 
Symptoms occur rapidly after intake of poisoned food and are manifested as 
preliminary numbness around the lips, which later affects the whole body and can 
lead to respiratory paralysis.[76] Its chemical core structure is a trialkyl 
tetrahydropurine and 30 derivatives are known.[77] 
Another example is cylindrospermopsin, which can be found in 
Cylindrospermopsis raciborskii. It is a cytotoxic and genotoxic alkaloid, which 
covalently binds to DNA and affects the liver, the kidneys and the lungs.[78] In 
addition, it is carcinogenic and inhibits protein synthesis.[79] The strong liver toxicity 
effect is explained by the oxidation by CYP450, which leads to a more potent 
metabolite.[80]  
Additional toxins, primarily produced by tropical and subtropical marine 
cyanobacteria like Oscillatoria, are, for example, lyngbyatoxin-a, debromoaplysiatoxin 
and aplysiatoxin, representing common dermatotoxins.[69] The typical common 
clinical symptom of these toxins is dermatitis, complemented by tumor promoter 
activity and protein kinase C activation in the case of debromoaplysiatoxin and 
aplysiatoxin, as well as gastrointestinal inflammation for lyngbyatoxin-a.[81,82] 
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Another class of toxins are the irritants. Some compounds with 
lipopolysaccharide core also fall in this category, as they represent a crucial 
component of the cell wall of all bacteria.[67] The toxicity effect occurs after a contact 
with these toxins and is manifested as an allergic response, gastroenteritis and 
inflammation.[83] These less serious toxic effects, in comparison to the above 
mentioned compounds, gives them less importance in research.[84] 
The last and best-studied compound class are the hepatotoxins. As mentioned 
above, cyanobacteria are known to be hepatotoxic and exposure to blooms cause 
typical clinical symptoms for liver damage, such as increased liver size, haemorrhage 
and blood pooling and deep-red coloration of the liver. Furthermore, enhanced 
activity of glutamate pyruvate transaminase/alanine aminotransferase, lactate 
dehydrogenase and alkaline phosphatase is observed.[85] 
The two common hepatotoxins are represented by the microcystins, whereby 
the main producers are Anabaena, Microcystis, Nostoc and Planktothrix, and by 
nodularin, produced by Nodularia spumigena, whereas this toxin shows a similar 
toxicity effect as microcystin.[86]  
A characteristic feature of both compounds is the strong inhibition effect of 
protein phosphatase 1 and 2A, as well as promotion of liver cancer.[87,88] The 
microcystins show a great variety of structures (80 derivatives known to date).[89] 
Beside a general core structure, two variable amino acids (Xaa, Yaa) lead to this 
great structural diversity.[90] Within this compound class, MC-LR (Xaa = Leu, 
Yaa = Arg) has an exceptional position as the most precisely studied microcystin, 
due to its high LD50 value (50 "gkg-1).[91] In fact, it is one of most potent and toxic 
compound produced by cyanobacteria and on this account the WHO set a guideline 
value of MC-LR in drinking water of 1 "gL-1.[92,93]  
Nodularin has a similar structure as microcystin, containing the Adda function 
(3-amino-9-methoxy-2,6,8-trimenthyl-10-phenyl-4,6-decadienoic acid), D-Glu, 
D-MeAsp, L-Arg and MeDhb. In contrast, to the microcystins a much smaller number 
of different structures has been described so far: only seven isoforms of this toxin 
have been reported.[75]  
In addition to the above-mentioned categorized toxins, cyanobacteria produce 
other classes of natural products, which share structural similarity and biological 
effects. These compounds can be further classified regarding their general core 
structure into aeruginosins, microginins, anabaenopeptins, cyanopeptolins, 
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microcystins, microviridins and cyclamides.[53] A large group of these toxins are the 
aeruginosins, which are trypsin-type serine protease inhibitors produced by 
Microcystis and Oscillatoria.[94,95] More than 40 variants are known up to date, and 
the characteristic core structure of this peptide class contains the unusual amino acid 
2-carboxy-6-hydroxyoctahydroindole (Choi) and hydroxyphenyl-lactic acid (Hpla) or 
lactic acid (Pla), further a variable amino acid (Leu, Ile, Phe, or Tyr) and an arginine 
or arginine derivative (agmatine, ariginol or 3-aminoethyl-1-N-amidino-#3-
pyrroline).[96] Another group of serine protease inhibitors are the cyclic peptides 
belonging to the group of cyanopeptolins, which have the amino acid 3-amino-
6-hydroxy-2-piperidone (Ahp).[97] These toxins show a great structural diversity based 
on the variation of several amino acids as well as derivatization, like sulfonation and 
chlorination.[98,99] 
The synthesis of these biomolecules is mostly performed by large enzyme 
complexes, the nonribosomal peptide synthetases (NRPS) or a combination of 
polyketide synthases and NRPSs systems.[100] The gene clusters of those 
synthetases contain highly conserved NRPS operons, comprising of, for example the 
mcyABC gene cluster for microcystin production within the different strains and thus 
suggest a horizontal gene transfer as an explanation for the similarity of the produced 
compounds.[90,101] The compounds produced by the NRPS pathway are further 
characterized by a remarkable structural variety within one class, which is not only 
resulting from variations in the amino acid sequence but also from modifications like 
methylation, glycosylation, chlorination or sulfation.[53] Nevertheless, ribosomal 
peptide synthesis and posttranslational modification is also suggested for some 
cyanobacterial peptides, as it is the case for microcyclamides, and microviridins.[102] 
Recently, !-N-methylamino-L-alanine, a neurotoxic amino acid produced by 
cyanobacteria, received attention as it is considered to be a trigger for human 
neurological diseases, such as Amyotrophic Lateral Sclerosis, Parkinson’s and 
Alzheimer’s disease.[103,104] These diseases seem to be initiated by an overactivation 
of neuroexcitatory glutamate receptors, which leads to damage of the neurons.[105] 
Despite all the research done on cyanobacterial toxins, the ecological and 
biological role of these compounds is still under investigation. Today the purpose of 
toxin production is mainly linked to the protection against grazers, e.g. against the 
waterflea Daphnia.[106-108] In contrast to this theory, phylogenetic analyses suggests 
that the synthetase genes developed simultaneously with the housekeeping genes 
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and thus are older than grazers.[109] They are also thought to act as allelochemicals 
to repel other photosynthetic competitors or for cell signalling or iron scavenging, 
since the long existence of these compounds and the effort for their production 
hypothesize a fundamental biological role.[110,111] In both cases, the existence of 
mutants of cyanobacteria, which have lost the ability to produce microcystin by 
inactivation of the mycrocystin synthetase through mutations in the gene cluster, 
could exclude the toxic function of microcystin.[112] This circumstance is even more 
complex, as non-toxic cyanobacteria exist and form blooms.[113,114] Therefore, the 
missing "final explanation" for the purpose of the toxin production renders toxic 
cyanobacteria still a mysterious species. Many things regarding their toxicity are 
known but nevertheless the challenge is to answer more open questions and resolve 
the last riddles, which this mysterious organisms preserves. 
!!
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1.4 Overview  !
In this thesis, open questions regarding cyanobacterial toxins are addressed. The 
projects involve the isolation, characterization, derivatization and biological 
evaluation of various toxic compounds derived from cyanobacteria. It is divided into 
4 chapters, each representing a separated research topic. 
 
Chapter 2 is addressing the general chemical behaviour of an arginine moiety in a 
peptide. It involves the development of a standardized method for efficient 
modification of the guanidinium group in native peptides. 
 
Chapter 3 describes the successful derivatization of the cyanobacterial toxin 
microcystin-LR. Furthermore, it contains biological tests to examine its possibly 
changed behaviour towards biological targets. First applications in zebrafish (Danio 
rerio) were tested by our cooperation partner Susanne Faltermann (University of 
Applied Sciences and Arts Northwestern Switzerland).  
 
Chapter 4 includes the structure elucidation of an unknown peptide isolated from 
cyanobacteria. It is estimated to be a replacement of microcystin in non-microcystin 
producing strains. The isolation was performed by our cooperation partner Esther 
Kohler (University of Zurich).  
 
Chapter 5 focuses on the chemical modification of the cyanobacterial toxin 
Cyanopeptolin 1020. 
!!
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2.1 Introduction 
 
Countless peptides are produced by various species through all domains of life. In 
fact, they are one of the main compound classes of natural products. A great 
diversity of structure and function is reached mainly by only 20 natural amino acids, 
and expanded by the nonribosomal synthesis in posttranslational modification or 
incorporation of unnatural amino acids.[1,2] The common feature peptides share is the 
backbone structure consisting of amide bonds, nevertheless a great variety can be 
achieved by sequence variation and length of the amino acid chain as well as the 
folding. Since these unique compounds are an integral part of many biological 
processes, they are one of the building blocks of life, and their different functions 
ranges from transport to signalling and defence.[3] Being involved in many 
biochemical processes in the body, peptides play an important role as inherent part 
as key compounds in a variety of research fields such as drug discovery, chemical 
biology, and medicinal applications.[4,5] The birth of peptide chemistry started in 1901 
with the coupling reaction of two amino acids to a dipeptide done by Emil Fischer, the 
father of Biochemistry.[6] The improvement of the method by the development of 
coupling reagents, protecting groups and auxiliaries to prevent racemisation, helped 
developing strategies for the synthesis of more complex peptides The field grew 
rapidly with the work of Merrifield, who introduced the solid-phase peptide synthesis 
in 1963. That not only allowed a faster and cleaner synthesis of peptides but also 
made automation of this reaction possible (Scheme 2.1).[7] For this break-through in 
synthetic chemistry, Robert Bruce Merrifield received the Nobel price in 1984. Using 
this methodology it was possible to synthesize peptides of around 70 amino acids 
within few hours.  
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Scheme 2.1. Solid-phase peptide synthesis (PG: Protecting group) 
 
The chain length limitation of this methodology was later circumvented by 
discovering the chemical ligation method, which allowed the coupling of two 
medium-size peptide fragments in a larger biopolymer (Scheme 2.2). This procedure 
was first reported by Wieland and later used, refined and modified by Kemp, 
Schnölzer and Kent.[8,9]  
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Scheme 2.2. Chemical ligation of two peptide fragments 
 
Nowadays, peptide chemistry grew to a large scientific field, and methods for 
improving the synthesis are still explored and discovered.[10-14] In addition, the 
chemical modification of peptides has developed as a complementary area of 
research with a great significance. Molecules bearing different tags (fluorophore, 
biotin, polyethylene glycol) are crucial for various applications, such as mechanistic 
studies or tracing the compound in a living organism. Also the derivatization of 
biologically active substances to improve, for example the activity, remains to be a 
great challenge, particularly in medicinal chemistry.[15] The modification in peptides is 
frequently carried out on nucleophilic side-chains, such as NH2, SH or OH in Lys, 
Cys, Ser, Thr, Glx or Asx residues.[16-21] The arginine moiety is rarely used as a 
modification site, due to its high pKa value of the protonated base (pKa ! 12.5) and 
the reduced reactivity towards electrophiles. The known procedures in literature 
mainly focus on modification of the arginine alone rather than functionalization of 
arginine-containing peptides.[22-31] An example of a direct procedure for arginine 
side-chain modification is the glyoxal approach.[26,27,30] Unfortunately, this strategy 
involves rather sensitive intermediates and results in low yields. Another widely used 
method employs sodium or potassium hydroxide to deprotonate the guanidinium 
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group, thereby increasing its nucleophilicity.[28,32] Such highly basic conditions are, 
however, not compatible with many base-sensitive functions and result in 
complications such as isomerization and degradation. NEt3, DBU or Hünig’s base 
(N,N-diisopropylethylamine) are alternatives to the hydroxide bases, however, for 
some more complex systems, especially on a small scale, those methods often result 
in low reactivity and therefore compromised yields.[22-31]   
In this context, and with regards to our research project to modifying MC-LR 
on the arginine function, a facile and straightforward method label arginines in 
peptides would allow modification of peptides that cannot be labelled with current 
methods. For the development of such a procedure, we first focused on protected 
arginine to screen different conditions. Afterwards, we investigated the scope and 
limitations of the method by examining the compatibility of functional groups and 
restrictions in the size of the peptides with various penta- to hepta-peptides. All 
promising modification routes and the final method were then used for the side-chain 
modification of MC-LR (Chapter 3).  
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2.2 Results and discussion 
 
2.2.1 Strategy 
 
The strategy for the method development was to study compatibility by incrementally 
increasing the substrate complexity. We hence set out to investigate the reaction 
behaviour of the guanidinium moiety in protected arginine. Labelling of the Arg 
guanidinium group via, for example acylation, is challenging because of the high pKa 
value of the protonated base (pKa ! 12.5). To ensure fast deprotonation of the 
guanidinium group, it was crucial to find a base sufficiently strong to deprotonate the 
guanidinium group, but mild enough to prevent degradation of the sensitive peptides. 
For studying the reactivity of the arginine group towards electrophiles and diketones, 
we started with protected arginine.  
Sulfonyl chlorides were first attempted on Boc-Arg-OH (Scheme 2.3).  
 
 
 
 
 
 
Scheme 2.3. General procedure for arginine labelling with sulfonyl chlorides 
 
A reaction with dansyl chloride (2 eq.) with 4 molL-1 KOH at room temperature 
in acetone showed that the strong basic conditions led to deprotection of the amide 
and thus to undesired side reactions (Entry 1, Table 2.1). Even a change to a milder 
base, such as a NaHCO3/Na2CO3 (pH = 10.8) buffer system, formed also the free 
amine (Entry 1). One of the main problems was the instability of the Boc-group with 
strong aqueous bases. Furthermore, the fluorophore used to hydrolyse rather quickly 
under these conditions. 
Because of these drawbacks, we decided to use a more stable protecting 
group for the amine function such as a Bz-group (Bz-Arg-OMe). We first focused on 
diketones and tried the reaction with glyoxal (40 %) and a NaHCO3/Na2CO3 (pH = 9) 
buffer system in acetone at 40 °C (Scheme 2.4, Entry 3).  
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Scheme 2.4. General procedure for arginine labelling with diketones 
 
This condition showed no conversion of the starting material. The change from 
glyoxal to acetylacetone (10 eq.), in attempt to obtain a more stabilized six-
membered ring, led also to no conversion (Entry 4). A last approach was made with 
phenylglyoxal (1.5 eq.) at room temperature (Entry 5). A product formed after 
15 minutes but it decomposed rather quickly (followed by TLC). Unfortunately no 
pure compound could be isolated due to its instability.  
 Our next step was changing from diketones to electrophiles, which can form 
an sulfonamide bond with the guanidinium group, such as dansyl chloride (2 eq.) in a 
NaHCO3/Na2CO3 (pH = 9) buffer system in dry acetone at room temperature and 
40 °C (Entry 6). No conversion of the starting material was observed under these 
conditions. An attempt to carry out the reaction in different solvents (THF, CH2Cl2, 
EtOAc and DMF) was also unsuccessful (Entry 7-10). Another set of strong basic 
conditions, 4 molL-1 KOH in acetone at room temperature, caused deprotection of the 
methylester, which then reacted with dansyl chloride (Entry 6). In addition, a partial 
degradation of dansyl chloride was observed. Using the NaHCO3/Na2CO3 
(pH = 10.8) buffer system in acetone or Na2CO3 (pH = 12) at room temperature to 
obtain milder conditions led to 2.1 in a small yield (< 10 %, Entry 6).  
One reason for that could be the fast hydrolysis of dansyl chloride. To verify 
this hypothesis, we used NEt3 (4 eq.) in DMF or pyridine, to prevent the competing 
hydrolysis of the sulfonyl chloride group (Entry 9). While using pyridine as base 
resulted in no conversion, the use of NEt3 showed similar yields as with the buffer 
system. The use of different solvents, such as THF, EtOAc or CH2Cl2 showed no 
improve of yield or even to formation of desired product (Entry 7-10). Likewise, the 
increase of the reaction temperature to 40 °C or to reflux could not significantly raise 
the yield.  
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Figure 2.1. Synthesized test substrates 
 
Next, we subjected the Bz-Arg-OMe to a less reactive sulfonyl chloride in 
order to improve the yield. In a first attempt, we used the NaHCO3/Na2CO3 
(pH  = 10.8) buffer system in acetone with lissamine rhodamin B (2 eq.). However, no 
reaction was observed in this experiment (Entry 12). A change to DMF and NEt3 
(4 eq.) led to some conversion of the starting material, but due to the high polarity of 
the newly formed product, the isolation of the latter was unsuccessful (Entry 13).  
In addition, we also tested regular peptide coupling conditions (Scheme 2.5).  
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Scheme 2.5. General procedure for arginine labelling with peptide coupling conditions 
 
Bz-Arg-OMe was treated with rhodamine B (1 eq.) in DMF and PYBOP (1 eq.) 
in NMM at room temperature, but also with these conditions no product was 
observed (Entry 14). Rhodamine B (1 eq.) in MeCN, N-hydroxysuccinimide (1.5 eq.) 
and EDC (1.5 eq.) led also to no product formation (Entry 15). In summary, only the 
reaction with dansyl chloride led to a promising result. Unfortunately, this method 
showed very low yields, maybe due to side reactions of dansyl chloride, and the poor 
solubility of the Bz-Arg-OMe.  
With this in mind, we changed the model substrate once more. We chose 
Bz-Arg-OEt, as this derivative has better solubility and stability. First, the diketones, 
as described above, were tested. We started with phenylglyoxal (1 eq.) and the 
NaHCO3/Na2CO3 (pH = 10.8) buffer system in acetone at room temperature 
(Entry 16). Only traces of product could be observed in this attempt. The same 
observation was made when using acetylacetone (15eq) (Entry 17). A peptide 
coupling approach, using rhodamine B (1 eq.), N-hydroxysuccinimide (2.5 eq.), EDC 
(2.5 eq.) and NEt3 (4 eq.) in MeCN, led to a small conversion (Entry 18). Also the 
use of DMAP did not improve the reaction. 
As the reaction with sulfonyl chlorides showed product formation with 
Bz-Arg-OMe, we investigated the reaction with Bz-Arg-OEt, dansyl chloride (3 eq.), 
DBU (12 eq.) and DMAP (catalytic) in DMF, which led to no improvement of the yield 
(Entry 19). Other bases, such as the NaHCO3/Na2CO3 (pH = 10.8) buffer system, 
NEt3 (4 eq.) and pyridine (excess), were tested, but none showed an improvement 
(Entry 20). Furthermore, a change of the sulfonyl chloride compound to lissamine 
rhodamin B (1 eq.) using NEt3 (4 eq.) in DMF at room temperature showed no 
conversion (Entry 21). The use of DBU (12 eq.) showed only traces of the desired 
product (Entry 21). The electrophilic nature of the label was changed by using 
isothiocyanates (Scheme 2.6).  
 
R1
N
H O
NH
HN NH2
R2
H
N R1
N
H O
NH
HN
H
N
R2
H
N
HO
O
O
R3
baseR3
coupling
reagent
!!
2 Arginine Modification 
!
! !
57 
 
 
 
 
 
Scheme 2.6. General procedure for arginine labelling with isothiocyanates 
 
Rhodamine B, NCS (1 eq.) was used in combination with DBU (6 eq.) or 
2-(tert-butyl)-1,1,3,3-tetramethylguanidine base (Barton's base) (6 eq.) in DMF at 
room temperature: in the last setup traces of product were observed (Entry 21). 
Next, the succinimidyl group was used as activated ester, as they are known to have 
excellent reactivity towards nucleophiles under mild conditions (Scheme 2.7).[33]  
 
 
 
 
 
 
Scheme 2.7. General procedure for arginine labelling with succinimidyl esters 
 
First we subjected Bz-Arg-OEt to 2,5-dioxopyrrolidin-1yl N-methylcarbamate 
(2.5 eq.) and DBU (6 eq.) in DMF at 40 °C, no product could be observed (Entry 22). 
We then performed the reaction with N-(benzylcarbonyloxy)succinimide in DMF and 
DBU (10 eq.) at 40 °C (Entry 23). Monitoring by LC-MS confirmed the desired 
product formation. However, the change to NEt3 (10 eq.) in MeCN or DMAP 
(catalytic) as additive in DMF showed no improvement (Entry 24,25). Intriguingly, the 
use of the Barton’s base (10 eq.) in DMF showed full conversion of the starting 
material to the desired product 2.2 (Entry 26). This commercially available base 
proved to act as an ideal proton acceptor. The advantage of the Barton’s base, which 
is characterized by its poor nucleophilicity and a pKa value of 14, is its structural 
similarity with the guanidinium group. That assures complete and fast deprotonation 
of the Arg guanidinium group and enables the nucleophilic attack on the activated 
esters. 
R1
N
H O
NH
HN NH2
R2
H
N R1
N
H O
NH
HN
H
N
R2
H
N
R3
O
O
R3base
O
N OO
R1
N
H O
NH
HN NH2
R2
H
N R1
N
H O
NH
HN
H
N
R2
H
N
N
C
S
HNbaseS R3
R3
!!
2 Arginine Modification 
!
! !
58 
With this efficient base identified, we tested different solvents, such as MeCN, 
EtOAc, THF, CH2Cl2, DMSO and DMF, whereby DMSO and DMF appeared to be the 
best (Entry 27-31). One disadvantage of DMSO it behaves as penetration enhancer, 
which is especially problematic while working with potent toxins. For this reason the 
use of DMF was preferred. Additionally various reaction temperatures were 
investigated: room temperature, 40 °C and 80 °C, whereby 80 °C showed full 
conversion of the starting material (Entry 26,32,33). A temperature of 40 °C turned 
out to be the compromise between reaction rate and stability of the reactants. 
With our optimized conditions, we were curious if Barton’s base is mild enough 
to acylate sensitive peptides. Additionally, we wanted to explore if a free carboxylic 
function is compatible with the developed method. Therefore, Boc-Arg-OH was 
treated with N-(benzylcarbonyloxy)succinimide (2 eq.) and Barton’s base (10 eq.) in 
DMF at 40 °C (Entry 2). We were pleased, that these conditions led to no 
deprotection of the Boc-group and yielded the desired product 2.3.  
We next investigated the scope and limitations of this method, especially to 
explore the range of compatible functional groups. A number of penta- to hepta-
peptides, containing various functionalized amino acids (Ser, Glu, Lys, Cys, His, etc; 
2.7-2.15), were synthesized by the standard solid-phase methodology (Figure 2.2). 
For synthetic reasons, an acetyl protecting group for primary amines was used. 
Furthermore, we wanted study if the size of the electrophile poses a limitation to the 
developed method, as we planned to attach mainly large fluorophores to the 
peptides.  
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Figure 2.2. Synthesized peptide substrates 
 
For this purpose, we subjected N-Ac-Arg-OH to the fluorophore Alexa 
488 (1 eq.) with Barton’s base (10 eq.) in DMSO (due to the low solubility of the 
fluorophore) (Entry 34). We were pleased to see that the product 2.4 was formed in 
42 % yield. The change to carboxyfluorescein (2 eq.) or 7-(diethylamino)coumarin-
3-carboxylic acid N-succinimidyl ester and Barton’s base in DMF led to the formation 
of the product 2.5 or 2.6 in 41 % and 25 % yield, respectively (Entry 35,36).  
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Scheme 2.8. General procedure for arginine labelling 
 
In summary we developed an efficient and practically facile derivatization 
method for the guanidinium moiety in arginine. This method allows modification of 
arginine containing peptides with a variety of biologically relevant labels, such as 
fluorescent moieties, diazirine and biotin (Scheme 2.8). 
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Table 2.1. Different conditions tested with protected arginine 
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2.2.2 Synthesis of the peptide substrates 
 
With optimized conditions for arginine modification in hand, we wanted to 
investigate the scope and limitations of the method with focus on functional groups 
compatibility. The synthesis of Arg-containing peptides was done following the 
standard solid-phase methodology. The synthesis of a number of penta- to 
hepta-peptides was in adequate yields. All peptides contained a phenylalanyl residue 
to allow UV detection and an acytylated glycin at the N-terminal position to prevent 
side reactions. The majority of the peptides contained one arginine in the sequence 
(compound 2.7-2.9, 2.11-2.15), whereas one peptide featured two arginine side 
chains (2.10, Figure 2.2). Purification in all cases was done by preparative HPLC. 
 
2.2.3 Synthesis of the modified peptides 
 
The synthesized peptides were first subjected to acylating conditions with the mixed 
isomer 5(6)-carboxyfluorescein succinimide. The reaction was performed by 
dissolving the peptides in dry DMF followed by addition of Barton’s base. 
Subsequently, the mixture was stirred for 15 minutes to ensure complete 
deprotonation of the guanidinium group followed by dropwise addition of the 
activated ester. The reaction was stirred for one (2.16, 2.17, 2.18, 2.20, 2.21 and 
2.29) or eight hours at 40 °C. We observed, that the reaction vial played a crucial role 
for the reaction time. The change of the reaction vessel from a small cylindrical insert 
(300"l volume) to a 1.5 mL HPLC vial led to an acceleration of the reaction time from 
eight to one hour. The volatiles were removed under reduced pressure and the 
remaining residue was dissolved in water and directly purified by RP-HPLC to give 
labelled peptides in moderate to good yield (> 95% purity). The use of a 
semi-preparative column with one injection of crude product led to 80 % yield. The 
pentapeptide 2.6 was successfully modified to give acylated peptide 2.16 in good 
yields (81 %).  
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Figure 2.3. Peptides modified with carboxyfluorescein (green)  
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The presence of either a Glu residue (to give compound 2.17) or a Ser residue (as 
in 2.18) did not affect the acylation of the Arg, as the guanidinium group was 
preferred over both CO2H and OH groups.  
It should be pointed out that all peptides were obtained with free C-termini, i.e. 
carboxylate groups, and modification of the C-terminus was never observed. 
Additionally the presence of a His residue in peptide 2.19 was well tolerated, and the 
nucleophilic imidazole ring did not result in side reactions to the desired Arg 
modification. 
Peptides containing two Arg residues also did not affect the method, and 
increasing the corresponding equivalents of base allowed for a smooth conversion to 
a bis-labelled peptide 2.20. In addition, longer peptides such as heptapeptide 2.21 
were obtained, as well as the peptide 2.22 carrying the non-proteinogenic Dha amino 
acid (dehydroalanine). This is important, as the presence of the #,$-unsaturated 
acceptor could interfere with various nucleophiles in the reaction.[34] All of these 
amino acids are frequently found in peptides of biological interest. The limitations of 
the method were observed in the presence of Lys or Cys residues, as their side 
chains react with the acylating agent. However, we are confident that these 
limitations could be overcome by a protection, i.e. as an imine for Lys and a disulfide 
for Cys, which would then be removed in situ after derivatization of Arg. 
We next evaluated the scope of the acylating agents, both with regard to the 
nature of the activated carboxylate derivative and its suitability for conjugation. While 
the studies for peptides 2.16-2.24 have been carried out with N-hydroxysuccinimide 
esters, we have also evaluated the use of p-nitrophenylesters. The corresponding 
biotin derivatives were prepared and subjected to the same reaction conditions as 
described before. The corresponding peptides 2.25 and 2.26 biotinylated at the Arg 
residue were obtained in similar yields as for the fluorescent derivatives.  
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Figure 2.4. Peptides modified with a biotin (blue)  
 
A third class of molecular probes, the sensitive diazirin-tag was also successfully 
introduced using this method, and the peptides 2.27 and 2.28 bearing a photoaffinity 
label at the Arg position were prepared. 
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Figure 2.5. Peptides modified with a diazirin (red)  
 
We then sought to apply this method for the fluorescent labelling of a bioactive 
peptides of clinical importance. Labelling of such widely used peptides could allow to 
monitor their distribution, both in a patient or in the environment. For this purpose, we 
selected the commercially available nonapeptide leuprolide acetate (2.29).[35] This 
biologically active peptide is an agonist of the luteinizing hormone-releasing receptor 
and is in clinical use for a variety of indications related to the suppression of 
luteinizing hormone, in particular prostate cancer, endometriosis, central precocious 
puberty and in vitro fertilization techniques.[35] Recent experiments suggest that 
leuprolide possesses neurotrophic properties, which is of interest in the context of our 
research program on small-molecule neurotrophin mimics.[36,37] From a chemical 
point of view, leuprolide (2.29) contains a variety of functionalized amino acids that 
could interfere with our acylation protocol. 
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 Using this method, we were able to selectively acylate leuprolide (2.29) at the 
guanidium side chain of arginine; the fluorescently labelled leuprolide analogue 2.30 
was obtained after HPLC purification in high purity (>95 %) (Figure 2.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Direct and selective labelling of leuprolide (2.29) with a fluorescent derivative to give 
derivative 2.30 
The presence of pGlu, His, Trp, Ser and Tyr residues did not interfere with Arg 
labelling, which underlines the power and the selectivity of the presented method. 
MS-MS data (chapter 7.4.) further supports our assignment of the product.  
 
2.2.4 Expanding the scope of the method 
 
As pointed out before, the developed method is not suitable for peptides 
containing strong nucleophilic groups such as primary amines (Lys). We envisioned 
an orthogonal protecting group like Boc would help us overcome this limitation. We 
first installed the Boc protecting group under basic conditions with before applying 
our method. We were pleased to see, that the guanidinium group of arginine got 
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efficiently labelled over the protected primary amine. MS-MS experiments supported 
the formation of the desired product (7.4). 
After deprotection under acidic conditions, we obtained the arginine labelled peptide 
2.33 in 33 % overall yield (Figure 2.7).  
 
 
 
 
  
 
 
 
Figure 2.7. Modified peptide with carboxyfluorescein (green) on the arginine moiety 
 
2.2.5 Photochemical properties of leuprolide with carboxyfluorescein 
 
After successfully labelling the nonapeptide leuprolide with carboxyfluorescein, we 
investigated the photochemical properties of compound 2.30, as we needed it later 
for uptake studies in Daphnia magna. The fluorescent spectrum is shown in 
Figure 2.8. The maximum absorption of the derivative was found at 502 nm and the 
maximum emission is located at 535 nm.  
 
 
Figure 2.8. Spectral profile of compound 2.30 
 
35
9
40
9
45
9
50
9
55
9
60
9
65
9
0.00
0.05
0.10
0.15
0.20
Absorbtion
Emission 535 nm
Extinction 327 nm
Extinction 502 nm
wavelength [nm]
In
te
ns
ity
 [A
U
) 
H
N
O
N
H O
H
N
O
N
H O
NH
HN
H
N
O
OH
O
NH
NH2
2.33 (33%)
O Flu
•TFA !
Absorption 
Em ssion 535 nm 
Ex itation 502 nm 
Ex itation 327 nm !
!!
2 Arginine Modification 
!
! !
69 
The colour space chromaticity diagram is shown in Figure 2.9. The 
fluorescence of the peptide is located at the yellowish-green range (x = 0.35, 
y = 0.63). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9. A: CIE colour space chromaticity diagram of Leuprolide-(6-FAM) 2.30 B: 
Fluorescent picture of Leuprolide-(6-FAM) 2.30 
 
In addition, the quantum yield of compound 2.30 was determined as it is an 
important parameter of the fluorescence intensity at the minimum concentration for 
biological experiments. Leuprolide-(6-FAM) had a quantum yield of % = 0.28 
(Ex: 493 nm), which allows no large dilutions for high enough sensitivity of the 
measurements. 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
!!
2 Arginine Modification 
!
! !
70 
2.2.6 Uptake studies in Daphnia magna  
 
In order to study the environmental fate of the leuprolide derivative 2.30, we chose 
Daphnia magna as a test organism. Daphnia magna is a small grazing crustacean, 
which is standardly used as a model in ecotoxicology studies.[38] The labelled peptide 
2.30 was dissolved in the medium, and the 48 h old animals were subsequently 
exposed to this dilution for three and six hours. The living animals were washed and 
immobilized in 1 % agarose gel for microscopic analysis using confocal microscopy. 
As seen in images A and B, the labelled compound 2.30 had entered the digestive 
tract of the animal (Figure 2.10). Furthermore, uptake into the cells of the ventral 
ceca (hepatopancreas) has occurred, which requires passing of the peritrophic 
membrane (C in Figure 2.10).[39] More interestingly, the hormone is first distributed in 
the entire gastrointestinal tract, whereas after six hours, the compound mainly 
accumulates in the cecum. 
 
 
 
 
 
 
 
Figure 2.10. Exposure of D. magna to fluorescently labelled leuprolide derivative 2.30            
A: Distribution after 3h B: Distribution after 6h C: Optical magnification of B  ! !
A B C 
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2.3 Conclusion 
 
 In conclusion, we have developed a facile and straightforward method for the direct 
labelling of the guanidinium side-chain of arginine moieties in native peptides. This 
method relies on the use of Barton’s base, which matches the reactivity of the 
guanidinium group in the substrate due to the similar chemical structure and higher 
basicity.   
Furthermore, we were able to introduce various biologically interesting tags 
(fluorophores, diazirine and biotin) in yields compared to current methods. 
Additionally, a series of peptides containing Glu, Ser, His, Trp, Tyr or Dha residues 
carrying sensitive side-chains has been selectively acylated at the Arg residue using 
both N-hydroxysuccinimide and p-nitrophenyl esters. As a direct application, the 
clinically used nonapeptide leuprolide, a representative of a more complex peptide, 
was selectively acylated at the Arg residue. 
The method is affected by the presence of other strong nucleophiles (Cys, 
Lys). This could be overcome by initially protecting these functions using orthogonal 
protecting groups such as Boc-group. 
We are convinced the method will find various applications in biochemical, 
toxicological, pharmacological and environmental studies of Arg-labelled peptides 
and would open the door to many exciting new discoveries. 
 
!!
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2.4 Methods 
2.4.1 General  
 
The following reagents were purchased and used as received: Amino acids 
(Bachem), Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt (Bachem), 2-chlorotrityl 
chloride resin (Bachem), NHS-diazirine (Thermo Scientific), seaplaque agarose 
(Lonza), all other chemicals were purchased from Sigma-Aldrich Co. and were of 
analytical grade. Biotin p-nitrophenylester and 2,5-dibromohexanediamide was 
prepared according to the literature.[40,41] Peptides 2.7-2.14 were synthesized by the 
standard Fmoc solid-phase procedure using a Syro I Peptide Synthesizer (Biotage). 
All reactions were carried out in oven-dried glassware under an atmosphere of argon. 
HPLC purifications of the peptides were carried out by preparative reverse phase 
HPLC using a Varian PrepStar HPLC with a Phenomenex Gemini NX-C18 10 µ 
(250 mm x 21.2 mm) column and a linear gradient: 5 % to 100 % CH3CN in H2O over 
30 min at a flow rate of 25 mL/min. HPLC purifications of the functionalized peptides 
were obtained on a Dionex P-680 HPLC System with a Phenomenex Gemini C18 5 µ 
(150 mm x 4.6 mm) column or a Phenomenex Gemini-NX C18 5 µ 
(75 mm x 21.2 mm) using a linear gradient: 5 % to 100 % CH3CN in 0.1 % TFA/H2O 
over 30 min or 20 min at a flow rate of 1 or 5 mL/min.  
1H-NMR spectra were recorded on a Bruker Avance 400 MHz or a Bruker Avance 
DRX 500MHz spectrometers at room temperature. Chemical shifts (!-values) are 
reported in ppm, spectra were calibrated related to solvent's residual proton chemical 
shift (DMSO, ! = 2.50). Multiplicity is reported as follows: s = singlet, bs = broad 
singlet, d = doublet, dd = doublet of doublet, t = triplet, m = multiplet. The coupling 
constant J is specified in Herz (Hz). UV-Vis Data was recorded on an Agilent 8453 
spectrophotometer, the fluorescence was measured on a Fluorimeter: Shimadzu 
5301PC spectrofluorophotometer and the quantum yield was determined on a 
Hamamatsu absolute PL quantum yield spectrometer C11347 Quantaurus_QY. 
HRMS spectra were recorded on a Bruker maXis 4G instrument or measured by the 
mass spectrometric service of the University of Bern on a Sciex QSTAR Pulsar mass 
spectrometer. HRMS spectra were obtained on a Bruker maXis 4G with ESI in 
positive or negative mode. MS-MS experiments were obtained on a Bruker Esquire 
3000 with ESI in positive mode.  
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2.4.2 Synthesis of the test-substrates 
 
 
 
  
 
 
Bz-Arg(Dansyl)-OMe, (2.1):  
Bz-Arg-OMe (2.0 mg, 6.8 µmol), NaHCO3/Na2CO3 (pH = 10.8) and dansyl chloride 
(3.7 mg, 13.7 µmol) were dissolved in acetone and stirred for 3 h at room 
temperature. Direct purification by HPLC afforded 2.1 (0.20 mg, 0.38 µmol, 6 %) as a 
yellow solid. HPLC: tR = 12.5 min; HRMS-ESI: calcd. for C26H32N5O5S+ [M+H]+: 
526.2119; found: 526.2121.  
 
 
 
 
 
Bz-Arg(N-succinimid)-OEt, (2.2):  
Bz-Arg-OEt (2.0 mg, 5.8 µmol), Barton's base (9.9 mg, 0.058 mmol) and 
N-(benzyloxycarbonyloxy)succinimid (1.5 mg, 5.8 µmol) were dissolved in 0.5 mL of 
dry DMF. The resulting reaction mixture was stirred for 2 h at 40 ° C. Direct 
purification by HPLC afforded 2.2 (2.4 mg, 5.4 µmol, 93 %) as a white solid. HPLC: tR 
= 9.1 min; HRMS-ESI: calcd. for C23H29N4O5+ [M+H]+: 441.2132; found: 441.2138.  
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Boc-Arg(N-succinimid)-OH, (2.3):  
Boc-Arg-OH (2.0 mg, 7.3 µmol), Barton's base (12.4 mg, 73 "mol) and 
N-(benzyloxycarbonyloxy)succinimid (3.6 mg, 14.6 µmol) were dissolved in 0.5 mL of 
dry DMF. The resulting reaction mixture was stirred for 2 h at 40 °C. Direct 
purification by HPLC afforded 2.3 (1.1 mg, 2.8 µmol, 38 %) as a white solid. HPLC: 
tR = 8.9 min; HRMS-ESI: calcd. for C19H29N4O6+ [M+H]+: 409.2082; found: 409.2082.  
 
 
 
 
 
 
 
 
N-Ac-Arg(Alexa488)-OH, (2.4):  
N-Ac-Arg-OH (0.50 mg, 2.3 µmol), Barton's base (4.0 mg, 0.023 mmol) and Alexa488 
N-succinimidyl ester (3.5 mg, 2.3 µmol) were dissolved in 0.5 mL of dry DMF. Direct 
purification by HPLC afforded 2.4 (0.70 mg, 1.0 µmol, 42 %) as a red solid. HPLC: 
tR = 7.5 min; HRMS-ESI: calcd. for C29H26N6O13S22- [M-H]2-: 365.0505; found: 
365.0501.  
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N-Ac-Arg(6-FAM)-OH, (2.5):  
N-Ac-Arg-OH (0.5 mg, 2.3 µmol), Barton's base (4.0 mg, 0.023 mmol) and 
5(6)-carboxyfluorescein N-succinimidyl ester (1.1 mg, 2.3 µmol) were dissolved in 
0.5 mL of dry DMF. The resulting reaction mixture was stirred for 2 h at 40 °C. Direct 
purification by HPLC afforded 2.5 (0.54 mg, 0.94 µmol, 41 %) as a red solid. HPLC: 
tR = 8.3 min; HRMS-ESI: calcd. for C29H27N4O9+ [M+H]+: 575.1773; found: 575.1772.  
 
 
 
 
 
 
N-Ac-Arg(coumarin)-OH, (2.6):  
N-Ac-Arg-OH (1.0 mg, 2.5 "mol), Barton's base (4.2 mg, 0.025 mmol) and 
7-(diethylamino)coumarin-3-carboxylic acid (0.28 mg, 1.3 µmol) were dissolved in 0.5 
mL of dry DMSO. The resulting reaction mixture was stirred for 2 h at 40 °C. Direct 
purification by HPLC afforded 2.6 (0.14 mg, 1.3 µmol, 25 %) as a yellow solid. HPLC: 
tR = 8.9 min; HRMS-ESI: calcd. for C22H30N5O6+ [M+H]+: 460.2191; found: 460.2193.  
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2.4.3 Synthesis of the peptide substrates 
 
2.4.3.1 General procedure 1 for the functionalization of 2-chlorotrityl chloride resin 
with carboxylic acids (GP1) 
 
The N-Fmoc-protected amino acid Fmoc-Gly-OH (3 eq.) and iPr2NEt (3 eq.) were 
added to the suspension of 2-chlorotrityl chloride resin (20 mg for Peptide 2.12, 2.13, 
2.14 or 200 mg for Peptide 2.7, 2.8, 2.9, 2.10, 2.11; loading: 2.5 mmol/g) in dry 
CH2Cl2 (2/20 mL). The reaction mixture was stirred for 2 h, the solvent was removed 
and the resin was washed with DMF (3x) and CH2Cl2 (5x). After drying in high 
vacuum, a functionalization of the resin over 95 % was indicated by mass analysis. 
 
2.4.3.2 General procedure 2 for peptide synthesis (GP2) 
 
The peptides 2.7-2.14 were synthesized on the 2-chlorotrityl resin on a 50 mmol 
scale. For the coupling reaction, Fmoc-Xxx-OH (3 eq.) and HCTU (3 eq.) were 
dissolved in DMF. iPr2NEt (16 eq.) was dissolved in NMP and the resulting solution 
was added with the activated amino acid to the amino-functionalized resin. The 
mixture was stirred for 1 h and washed with DMF (3x).  Fmoc deprotections were 
carried out with a solution of 20 % piperidine in DMF that was added to the resin and 
the reaction mixture was stirred for 3 min, the solvents were removed and the residue 
was treated again for 10 min with 20 % piperidine in DMF. Finally, the resin was 
washed with DMF (5x). Capping of the synthesized peptide was performed with 
Ac-Gly-OH. The peptide was cleaved from the solid support by stirring the resin in a 
1:1:8 mixture of AcOH, TFA and CH2Cl2 for 20 min. The solvents were then removed 
under high vacuum. Final overall deprotection of the free peptide was achieved by 
dissolving the residue in a mixture of 95 % aqueous TFA and Et3SiH. The resulting 
mixture was then stirred for 2 h. All volatiles were removed under reduced pressure. 
The residue was precipitated with Et2O and the isolated peptide was purified by 
HPLC.    
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N-Ac-Gly-Val-Phe-Arg-Gly-OH (2.7):  
The peptide 2.7 was synthesized according to GP2. HPLC purification gave the 
target peptide 2.7 (78 mg, 140 "mol, 27 %) as a white solid. HPLC: tR = 6.8 min; 
1H-NMR (400 MHZ, d6-DMSO 25 °C): 8.26 – 8.23 (m, 2H), 8.11 (d, J = 8.0 Hz, 1H), 
8.03 (t, J = 5.8 Hz, 1H), 7.95 (s, 1H, Arg-NH), 7.87 (d, J = 8.7 Hz, 1H), 7.27 – 7.15 
(m, 7H, Phe, Arg-NH), 4.54 – 4.48 (m, 1H, Phe-#), 4.32 – 4.26 (m, 1H, Arg-#), 
4.06 - 4.04 (m, 1H, Val-#), 3.77 – 3.66 (m, 4H; Gly-#), = 3.08 – 3.00 (m, 3H, Arg-!, 
Phe-$), 2.90 – 2.84 (m, 1H; Phe-$), 1.93 - 1.86 (m, 4H; Ac, Val-$), 1.76 – 1.49 
(m, 4H; Arg-$%), 0.71 – 0.68 (m, 6H; Val-%); HRMS-ESI: calcd. for C26H41N8O7+ 
[M+H]+: 577.3093; found: 577.3103.  
 
 
N-Ac-Gly-Val-Glu-Phe-Arg-Gly-OH (2.8):  
The peptide 2.8 was synthesized according to GP2. HPLC purification gave the 
target peptide 2.8 (52 mg, 70 "mol, 13 %) as a white solid. HPLC: tR = 6.5 min; 
1H-NMR 400 MHZ, d6-DMSO 25 °C): ! = 11.60 (bs, 1H, OH), 8.22 (d, J = 8.3 Hz, 
1H), 8.14 – 8.00 (m, 2H), 8.07 (s, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.69 (bs, 1H, 
Arg-NH), 7.22 – 7.14 (m, 5H, Phe), 4.54 – 4.49 (m, 1H, Phe-#), 4.31 – 4.26 (m, 1H, 
Arg-#), 4.22 – 4.13 (m, 2H, Val-#, Glu-#), 3.76 - 3.68 (m, 4H, Gly-#), 3.10 – 2.99 (m, 
3H, Arg-!, Phe-$), 2.87 – 2.80 (m, 1H, Phe-$), 2.19 – 2.13 (m, 2H, Glu-$), 
1.94 -  1.89 (m, 1H, Val-$), 1.84 (s, 3H, Ac), 1.71 – 1.48 (m, 6H, Arg-$%, Glu-$), 0.78 
(t, J = 7.1 Hz, 6H, Val-%); HRMS-ESI: calcd. for C31H48N9O10+ [M+H]+: 706.3519; 
found: 706.3528.  
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N-Ac-Gly-Lys-Phe-Arg-Gly-OH, (2.9):  
The peptide 2.9 was synthesized according to GP2. HPLC purification gave the 
target peptide 2.9 (60 mg, 100 "mol, 20 %) as a white solid. HPLC: tR = 2.6 min; 
1H-NMR (400 MHZ, d6-DMSO 25 °C): ! = 8.41 (d, J = 6.9 Hz, 1H), 8.24 (t, J = 5.7 Hz, 
1H), 8.18 (d, J = 8.0 Hz, 1H), 8.10 – 8.06 (m, 2H), 8.02 (s, 1H, Arg-NH), 7.79 (s, 2H, 
Lys-NH), 7.29 – 7.15 (m, 7H, Phe, Arg-NH), 4.47 - 4.41 (m, 1H, Phe-#), 4.31 – 4.26 
(m, 1H, Arg-#), 4.19 – 4.14 (m, 1H, Lys-#), 3.75 – 3.68 (m, 4H, Gly-#), 3.13 – 3.02 
(m, 3H, Arg-!, Phe-$), 2.95 – 2.93 (m, 1H, Phe-$), 3.13 – 3.02 (m, 2H, Lys-!), 1.86 
(s, 3H, Ac), 1.73 – 1.40 (m, 8H, Arg-$%, Lys-$%), 1.23 – 1.15 (m, 2H, Arg-$%, Lys-$%); 
HRMS-ESI: calcd. for C27H44N9O7+ [M+H]+: 606.3358; found: 606.3350.  
 
 
N-Ac-Gly-Phe-Arg-Arg-Gly-OH, (2.10):  
The peptide 2.10 was synthesized according to GP2. HPLC purification gave the 
target peptide 2.10 (43 mg, 70 "mol, 13 %) as a white solid. HPLC: tR = 2.3 min; 
1H-NMR (400 MHZ, d6-DMSO 25 °C): ! = 8.26 (t, J = 5.8 Hz, 1H), 8.20 (d, J = 7.9 Hz, 
1H), 8.10 (t, J = 5.8 Hz, 1H), 8.06 (d, J = 8.1 Hz, 1H), 7.99 (d, J = 7.9 Hz, 1H), 
7.54 -  7.51 (m, 2H, Arg-NH), 7.27 - 7.17 (m, 6H, Phe, Arg-NH), 4.55 – 4.49 (m, 1H, 
Phe-#), 4.33 – 4.26 (m, 2H, Arg-#), 3.79 – 3.68 (m, 3H, Gly-#), 3.55 – 3.49 (dd, 
J = 5.6 Hz, 16.5 Hz, 1H, Gly-#), 3.10 – 3.09 (m, 4H, Arg-!), 3.04 - 2.99 (s, 1H, 
Phe-$), 2.81 – 2.77 (d, J = 5.5 Hz, 1H, Phe-$), 1.82 (s, 6H, Ac), 1.75 – 1.43 (m, 8H, 
Arg-$%); HRMS-ESI: calcd. for C27H45N11O72+ [M+H+H]2+: 317.6746; found: 317.6754. 
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N-Ac-Gly-Phe-Val-Arg-Gly-Val-Gly-OH, (2.11):  
The peptide 2.11 was synthesized according to GP2. HPLC purification gave the 
target peptide 2.11 (63 mg, 90 "mol, 17 %) as a white solid. HPLC: tR = 2.82 min; 
1H-NMR (400 MHZ, d6-DMSO 25 °C): ! = 8.14 (t, J = 5.7 Hz, 1H), 8.07 (t, J = 6.0 Hz, 
2H), 8.02 (d, J = 8.2 Hz, 1H), 7.96 – 7.94  (m, 2H), 7.84 (d, J = 8.9 Hz, 1H), 7.51 
(t, J = 5.7 Hz, 1H, Arg-NH), 7.27 - 7.17 (m, 6H, Phe, Arg-NH), 4.62 – 4.58 (m, 1H, 
Phe-#), 4.33 – 4.27 (m, 1H, Arg-#), 4.22 – 4.15 (m, 2H, Val-#), 3.82 – 3.66 (m, 5H, 
Gly-#), 3.59 – 3.53 (m, 1H, Gly-#), 3.13 – 3.08 (m, 2H, Arg-!), 3.01 (dd, J = 4.53 Hz, 
13.9 Hz, 1H, Phe-$), 2.81 - 2.77 (m, 1H, Phe-$), 2.02 – 1.96 (m, 2H, Val-$), 1.82 
(s, 3H, Ac), 1.73 – 1.66 (m, 1H,  Arg-$%), 1.60 – 1.45 (m, 3H,  Arg-$%), 0.88 – 0.83 
(m, 12H, Val-%); HRMS-ESI: calcd. for C33H53N10O9+ [M+H]+: 733.3991; found: 
733.3989. 
 
 
N-Ac-Gly-Val-Arg-Phe-Ser-Gly-OH, (2.12):  
The peptide 2.12 was synthesized according to GP2. HPLC purification gave the 
target peptide 2.12 (43 mg, 100 "mol, 13 %) as a white solid. HPLC: tR = 8.2 min; 
1H-NMR (400 MHZ, d6-DMSO 25 °C): ! = 9.88 (s, 1H, OH), 8.38 – 8.34 (m, 2H), 
8.14 – 8.08 (m, 3H), 7.79 (d, J = 8.8 Hz, 1H), 7.26 – 7.16 (m, 7H, Phe, Arg-NH), 7.04 
(bs, 2H, Arg-NH), 4.54 - 4.48 (m, 1H, Phe-#), 4.36 – 4.30 (m, 1H, Arg-#), 4.23 – 4.15 
(m, 2H, Val-#, Ser-#), 3.79 – 3.69 (m, 3H, Gly-#), 3.55 – 3.44 (m, 3H, Gly-#, Ser-$), 
3.06 – 3.02 (m, 2H, Arg-!), 2.96 (dd, J = 13.6, 5.6 Hz, 1H, Phe-$), 2.86 (dd, J = 13.6, 
8.3 Hz, 1H, Phe-$), 1.93 – 1.88 (m, 1H, Val-$), 1.86 (s, 3H, Ac), 1.56 – 1.35 (m, 4H, 
Arg-$%), 0.78 (d, J = 6.8 Hz, 6H, Val-%); HRMS-ESI: calcd. for C29H45N9NaO9+ 
[M+Na]+: 686.3232; found: 686.3233. 
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N-Ac-Gly-Val-Cys-Arg-Phe-Gly-OH, (2.13):  
The peptide 2.13 was synthesized according to GP2. HPLC purification gave the 
target peptide 2.13 (18 mg, 30 "mol, 54 %) as a white solid. HPLC: tR = 7.2 min; 
1H-NMR (400 MHZ, d6-DMSO 25 °C): ! = 8.83 (s, 1H, Cys-SH), 8.43 (d, J = 8.7 Hz, 
1H), 8.18 – 8.11 (m, 2H), 7.91 - 7.85 (m, 2H), 7.68 (bs, 1H), 7.25 – 7.11 (m, 9H, 
Phe, Arg-NH), 4.50 – 4.18 (m, 4H, Phe-#, Arg-#, Ser-#, Val-#), 3.75 – 3.72 (m, 2H, 
Gly-#), 3.49 (d, J = 4.8 Hz, 2H, Gly-#), 3.08 – 2.95 (m, 4H, Arg-!, Ser-$, Phe-$), 2.80 
– 2.64 (m, 2H, Ser-$, Phe-$), 2.0 – 1.93 (m, 1H, Val-$), 1.84 (s, 3H, Ac), 1.57 – 1.41 
(m, 3H, Arg-$%), 1.23 – 1.16 (m, 1H, Arg-$%), 0.83 – 0.75 (m, 6H, Val-%); HRMS-ESI: 
calcd. for C29H46N9O8S+ [M+H]+: 680.3185; found: 680.3193. 
 
 
N-Ac-Gly-Phe-His-Ala-Arg-Gly-OH, (2.14):  
The peptide 2.14 was synthesized according to GP2. HPLC purification gave the 
target peptide 2.14 (25 mg, 40 "mol, 75 %) as a white solid. HPLC: tR = 3.2 min; 
1H-NMR (400 MHZ, d6-DMSO 25 °C): ! = 8.69 (s, 1H, His-NH), 8.32 (d, J = 8.0 Hz, 
1H), 8.26 – 8.19 (m, 2H), 8.16 - 8.06 (m, 3H), 7.65 (t, J = 5.6 Hz, 1H, Arg-NH), 7.27 
– 7.17 (m, 7H, Phe, His), 4.57 – 4.53 (m, 1H, His-#), 4.49 – 4.44 (m, 1H, Phe-#), 4.34 
– 4.24 (m, 2H, Ala-#, Arg-#), 3.84 – 3.68 (m, 3H, Gly-#), 3.57 – 3.52 (m, 1H, Gly-#), 
3.10 – 3.06 (m, 3H, Arg-!, His-$), 3.00 – 2.92 (m, 2H, His-$, Phe-$), 2.78 – 2.71 (m, 
1H, Phe-$), 1.83 (s, 3H, Ac), 1.77 – 1.71 (m, 1H, Arg-$%), 1.60 – 1.47 (m, 3H, 
Arg-$%), 1.24 (d, J = 7.0 Hz, 3H, Ala-$); HRMS-ESI: calcd. for C30H44N11O8+ [M+H]+: 
686.3369; found: 686.3362. 
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N-Ac-Gly-Val-Dha-Arg-Phe-Gly-OH, (2.15):  
Compound 2.13 (39 mg, 57 "mol) and 2,5-dibromohexanediamide (17 mg, 57 "mol) 
were dissolved in 1:1 MeCN:phosphate buffer pH = 8. The reaction was stirred at 
room temperature for 1 h. After 1 h the reaction mixture was heated up to 40 °C and 
stirred additional 1 h. HPLC purification gave the target peptide 2.15 (3.5 mg, 
5.0 "mol, 9 %) as a white solid. HPLC: tR = 7.4 min; 1H-NMR (500 MHZ, d6-DMSO 
25°C): ! = 9.28 (bs, 1H, OH), 8.62 – 8.22 (m, 6H), 7.31 (t, J = 9.05 Hz, 1H, Arg-NH), 
7.26 – 7.15 (m, 6H, Phe, Arg-NH), 6.08 (s, 1H, Dha-$), 5.55 (s, 1H, Dha-$), 
4.40 -  4.36 (m, 2H, Phe-#, Arg-#), 4.23 – 4.21 (m, 2H, Gly-#, Val-#), 3.81 – 3.71 (m, 
3H, Gly-#), 3.11 – 3.07 (m, 2H, Phe-$, Arg-!), 2.98 – 2.93 (m, 1H, Arg-!), 2.81(dd, J 
= 3.91, 10.25 Hz, 1H, Phe-$), 2.09 – 2.02 (m, 1H, Val-$), 1.84 (s, 3H, Ac), 
1.62 -  1.39 (m, 4H, Arg-$%), 0.87 – 0.84 (m, 6H, Val-%); HRMS-ESI: calcd. for 
C29H44N9O8+ [M+H]+: 646.3307; found: 646.3304.  
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2.4.4 Synthesis of the functionalized peptides 
 
2.4.4.1 General procedure 3 for the functionalization of the arginine residue of the 
peptides (GP3) 
 
To a solution of the peptide (1 eq.) in DMF (300 µL) were added Barton’s base 
(10 eq.) followed by a solution of the activated ester (1.5 eq.) in DMF (100 µL). The 
resulting mixture was stirred at 40 °C for 1h (2.16, 2.17, 2.18, 2.20, 2.21 and 2.29) or 
8h. All volatiles were removed under reduced pressure and the residue was 
subsequently purified by HPLC.  
 
 
N-Ac-Gly-Val-Phe-Arg(6-FAM)-Gly-OH, (2.16):  
According to the general procedure GP3 compound 2.16 was synthesized starting 
from compound 2.7 (1.0 mg, 1.7 µmol), Barton's base (2.9 mg, 17 µmol) and 
5(6)-carboxyfluorescein N-succinimidyl ester (1.2 mg, 2.6 µmol) were used. Direct 
purification by HPLC afforded 2.16 (1.3 mg, 1.4 µmol, 81 %) as a red solid. HPLC: 
tR = 9.5 min; HRMS-ESI: calcd. for C47H52N8O132+ [M+H+H]2+: 468.1821; found: 
468.1829.  
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N-Ac-Gly-Val-Glu-Phe-Arg(6-FAM)-Gly-OH, (2.17):  
According to the general procedure GP3 compound 2.17 was synthesized starting 
from compound 2.8 (1.0 mg, 1.4 µmol), Barton's base (2.4 mg, 14 µmol) and 
5(6)-carboxyfluorescein N-succinimidyl ester (0.99 mg, 2.1 µmol) were used. Direct 
purification by HPLC afforded 2.17 (1.3 mg, 1.6 µmol, 85 %) as a red solid. HPLC: 
tR = 11.3 min; HRMS-ESI: calcd. for C52H56N9O16- [M-H]-: 1062.3851; found: 
1062.3847.  
 
 
N-Ac-Gly-Val-Arg(6-FAM)-Phe-Ser-Gly-OH, (2.18):  
According to the general procedure GP3 compound 2.18 was synthesized starting 
from compound 2.12 (1.0 mg, 1.5 µmol), Barton's base (2.5 mg, 15 µmol) and 
5(6)-carboxyfluorescein N-succinimidyl ester (1.1 mg, 2.3 µmol) were used. Direct 
purification by HPLC afforded 2.18 (1.2 mg, 1.2 µmol, 83 %) as a red solid. HPLC: 
tR = 8.2 min; HRMS-ESI: calcd. for C50H54N9O15- [M-H]-: 1020.3745; found: 
1020.3729.  
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N-Ac-Gly-Phe-His-Ala-Arg(6-FAM)-Gly-OH, (2.19):  
According to the general procedure GP3 compound 2.19 was synthesized starting 
from compound 2.14 (2.0 mg, 2.9 µmol), Barton's Base (5.0 mg, 29 µmol) and 
5(6)-Carboxyfluorescein N-succinimidyl ester (2.1 mg, 4.4 µmol) were used. Direct 
purification by HPLC afforded 2.19 (0.98 mg, 0.94 µmol, 32 %) as a red solid. HPLC: 
tR = 7.6 min; HRMS-ESI: calcd. for C51H54N11O14+ [M+H]+: 1044.3846; found: 
1044.3839.  
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N-Ac-Gly-Phe-Arg(6-FAM)-Arg(6-FAM)-Gly-OH, (2.20):  
According to the general procedure GP3 compound 2.20 was synthesized starting 
from compound 2.10 (1.0 mg, 1.6 µmol), Barton's base (5.4 mg, 32 µmol) and 
5(6)-carboxyfluorescein N-succinimidyl ester (2.2 mg, 4.7 µmol) were used. Direct 
purification by HPLC afforded 2.20 (1.1 mg, 0.81 µmol, 42 %) as a red solid. HPLC: 
tR = 8.2 min; HRMS-ESI: calcd. for C69H64N11O19+ [M+H]+: 1350.4374; found: 
1350.4386.  
 
 
N-Ac-Gly-Phe-Val-Arg(6-FAM)-Gly-Val-Gly-OH, (2.21):  
According to the general procedure GP3 compound 2.21 was synthesized starting 
from compound 2.11 (1.0 mg, 1.4 µmol), Barton's base (2.4 mg, 14 µmol) and 
5(6)-carboxyfluorescein N-succinimidyl ester (0.99 mg, 2.1 µmol) were used. Direct 
purification by HPLC afforded 2.21 (1.2 mg, 1.1 µmol, 82 %) as a red solid. HPLC: 
tR = 10.9 min; HRMS-ESI: calcd. for C54H64N10O152+ [M+H+H]2+: 546.2271; found: 
546.2273.  
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N-Ac-Gly-Val-Dha-Arg(6-FAM)-Phe-Gly-OH, (2.22):  
According to the general procedure GP3 compound 2.22 was synthesized starting 
from compound 2.15 (0.99 mg, 1.4 µmol), Barton's base (2.4 mg, 14 µmol) and 
5(6)-carboxyfluorescein N-succinimidyl ester (0.99 mg, 2.1 µmol) were used. Direct 
purification by HPLC afforded 2.22 (0.56 mg, 0.56 µmol, 40 %) as a red solid. HPLC: 
tR = 8.7 min; HRMS-ESI: calcd. for C50H54N9O14+ [M+H]+: 1004.3785; found: 
1004.3772.  
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N-Ac-Gly-Val-Cys(6-FAM)-Arg-Phe-Gly-OH, (2.23):  
According to the general procedure GP3 compound 2.23 was synthesized starting 
from compound 2.13 (2.0 mg, 2.9 µmol), Barton's base (5.0 mg, 29 µmol) and 
5(6)-carboxyfluorescein N-succinimidyl ester (2.1 mg, 4.4 µmol) were used. Direct 
purification by HPLC afforded 2.23 (1.0 mg, 0.98 µmol, 34 %) as a red solid. HPLC: 
tR = 9.82 min; HRMS-ESI: calcd. for C50H56N9O14S+ [M+H]+: 1038.3662; found: 
1038.3663.  
 
 
N-Ac-Gly-Lys(6-FAM)-Phe-Arg-Gly-OH, (2.24):  
According to the general procedure GP3 compound 2.24 was synthesized starting 
from compound 2.9 (1.0 mg, 1.7 µmol), Barton’s base (2.9 mg, 17 µmol) and 
5(6)-carboxyfluorescein N-succinimidyl ester (1.2 mg, 2.6 µmol) were used. Direct 
purification by HPLC afforded 2.24 (0.67 mg, 0.66 µmol, 42 %) as a red solid. HPLC: 
tR = 9.8 min; HRMS-ESI: calcd. for C48H54N9O13+ [M+H]+: 964.3836; found: 964.3845.  
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N-Ac-Gly-Phe-Val-Arg(Biotin)-Gly-Val-Gly-OH, (2.25):  
According to the general procedure GP3 compound 2.25 was synthesized starting 
from compound 2.11 (1.0 mg, 1.4 µmol), Barton's base (2.4 mg, 14 µmol) and 
p-nitrophenylester (0.77 mg, 2.1 µmol) were used. Direct purification by HPLC 
afforded 2.25 (0.60 mg, 0.63 µmol, 47 %) as a red solid. HPLC: tR = 9.5 min; 
HRMS-ESI: calcd. for C43H67N12NaO11S2+ [M+H+Na]2+: 491.2330; found: 491.2331.  
 
 
N-Ac-Gly-Val-Glu-Phe-Arg(Biotin)-Gly-OH, (2.26):  
According to the general procedure GP3 compound 2.26 was synthesized starting 
from compound 2.8 (1.0 mg, 1.4 µmol), Barton’s base (2.4 mg, 14 µmol) and 
p-nitrophenylester (0.77 mg, 2.1 µmol) were used. Direct purification by HPLC 
afforded 2.26 (0.61 mg, 0.86 µmol, 47 %) as a red solid. HPLC: tR = 9.3 min; 
HRMS-ESI: calcd. for C41H62N11O12S+ [M+H]+: 932.4295; found: 932.4285.  
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N-Ac-Gly-Phe-Val-Arg(DA)-Gly-Val-Gly-OH, (2.27):  
According to the general procedure GP3 compound 2.27 was synthesized starting 
from compound 2.11 (1.0 mg, 1.4 µmol), Barton's base (2.4 mg, 14 µmol) and 
succinimidyl-diazirine (0.77 mg, 2.1 µmol) were used. Direct purification by HPLC 
afforded 2.27 (0.49 mg, 0.58 µmol, 43 %) as a red solid. HPLC: tR = 8.6 min; 
HRMS-ESI: calcd. for C38H59N12O10+ [M+H]+: 843.4472; found: 843.4482.  
 
 
N-Ac-Gly-Val-Glu-Phe-Arg(DA)-Gly-OH, (2.28):  
According to the general procedure GP3 compound 2.28 was synthesized starting 
from compound 2.8 (1.0 mg, 1.4 µmol), Barton's base (2.4 mg, 14 µmol) and 
succinimidyl-diazirine (0.49 mg, 2.1 µmol) were used. Purification by HPLC afforded 
2.28 (0.43 mg, 0.53 µmol, 38%) as a red solid. HPLC: tR = 8.2 min; HRMS-ESI: 
calcd. for C36H54N11O11+ [M+H]+: 816.3999; found: 816.4004.  
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Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg(6-FAM)-Pro-NHEt, (2.30):  
According to the GP3 compound 2.30 was synthesized starting from commercially 
available leuprolide 2.29 (1.0 mg, 0.83 µmol), Barton's base (1.4 mg, 8.3 µmol) and 
5(6)-carboxyfluorescein N-succinimidyl ester (0.56 mg, 1.2 µmol) were used. Direct 
purification by HPLC afforded 2.30 (1.01 mg, 0.64 µmol, 77 %) as a red solid. HPLC: 
tR = 10.4 min; HRMS-ESI: calcd. for C80H96N16O182+ [M+H+H]2+: 784.3539; found: 
784.3548.  
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2.4.5 Prevention of limitation of method 
 
 
 
N-Ac-Gly-Lys(Boc)-Phe-Arg-Gly-OH, (2.31): 
Compound 2.9 (1.0 mg, 1.7 µmol) was dissolved in water and Na2CO3 (0.30 mg, 
2.8 µmol). The solution was cooled down to 5 °C and BOC anhydride in dioxane 
(0.50 mg, 2.3 µmol) was added slowly. After the mixture was stirred for 1 h, the 
cooling bath was removed and the reaction was warmed to room temperature over 
night. Purification by HPLC afforded 2.31 (0.70 mg, 0.99 µmol, 64 %) as a white 
solid. HPLC: tR = 14.1 min; HRMS-ESI: calcd. for C32H52N9O9+ [M+H]+: 706.3883; 
found: 706.3890.  
 
 
 
N-Ac-Gly-Lys(Boc)-Phe-Arg(6-FAM)-Gly-OH, (2.32): 
According to the general procedure GP3 compound 2.32 was synthesized starting 
from compound 2.31 (0.50 mg, 0.71 µmol). Barton’s base (1.2 mg, 7.07 µmol) and 
5(6)-carboxyfluorescein N-succinimidyl ester (0.40 mg, 0.84 µmol) were used. Direct 
purification by HPLC afforded 2.32 (0.40 mg, 0.38 µmol, 53 %) as a red solid. HPLC: 
tR = 17.4 min; HRMS-ESI: calcd. for C53H62N9O15+ [M+H]+: 1064.4360; found: 
1064.4375. 
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N-Ac-Gly-Lys-Phe-Arg(6-FAM)-Gly-OH, (2.33):  
Final deprotection of compound 2.32 (0.20 mg, 0.19 µmol) was carried out in 50 % 
TFA over 2 h. Direct purification by HPLC afforded 2.33 (0.061 mg, 0.062 µmol, 
33 %) as a red solid. HPLC: tR = 12.2 min; HRMS-ESI: calcd. for C48H54N9O13+ 
[M+H]+: 964.3836; found: 964.3843.   
 
2.4.6 Uptake studies in Daphnia magna  
 
The uptake studies were carried out by using 48 h old Daphnia magna, that were 
exposed to an aqueous solution of compound 2.29 (6.9 "M). For each experiment, 
10 animals were placed in a 50 mL beaker in 15 mL M4 media with the labelled 
compound without food and incubated at 20 °C over 6 h. Samples were taken after 
3 h and 6 h, whereby the Daphnia were rinsed with fresh M4 media and immobilized 
afterwards on 1 % agarose gel. Imaging of the samples was performed on an 
Olympus Fluoview FV1000 confocal laser-scanning microscope with a 4x and 10x 
magnification. The excitation wavelength of the samples was 488 nm with 15 % laser 
transmission. Analyses of the pictures were carried out with FV 10-ASW Version 
03.00.02.00.
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3.1 Introduction 
 
In 1996, 52 dialysis patients died in Brazil because of treatment with cyanobacteria 
contaminated water.[1] In Argentina, a man suffered of intoxication symptoms after 
diving in a lake with a cyanobacteria bloom.[2,3] Such incidents are occurring more 
often due to global warming and eutrophication. Dangerous cyanobacterial growth 
begins to threaten safety and viability of the aquatic resources all over the world 
(Figure 3.1).  
 
 
 
 
 
 
Figure 3.1. Marion Reservoir, Kansas (Photo Credit: Jennifer L. Graham, USGS) 
 
Responsible for these blooms are certain types of microorganisms, the 
cyanobacteria, formerly called blue-green algae. After the death of the cyanobacterial 
colonies, a number of highly toxic molecules are released and thereby pollute fresh 
and marine waters, which creates a serious threat to the water supply, public health, 
livestock and wildlife.[4] This poses a great danger to humans, animals, and the 
ecosystem as a whole, as these toxins are highly chemically stable and 
water-soluble.[5] In humans, the toxic effects result in symptoms like nausea, 
dizziness, respiratory distress and skin itching and they can even cause severe 
diseases like liver damage or cancer.[4,6,7]  
Besides this, another problem arises from these toxins being able to enter the 
food chain via accumulation in fish, mussels or shellfish, eventually finding their way 
into the human body.[8] Over the past years, cases of cyanobacterial poisoning have 
been more and more frequently reported, whereby the regular intoxication occurs via 
oral intake, although other uptake mechanisms such as inhalation or skin contact are 
also possible.[9] 
The main toxin class thought to be responsible for a large number of these 
poisonings belongs to the microcystin family of cyclic peptides, a diverse compound 
class of more than 80 different derivatives known to date.[10] These molecules contain 
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the general structure cyclo(-D-Ala-Xaa-D-MeAsp-Yaa-Adda-D-Glu-Mdha-), whereby 
the two amino acid residues in position 2 and 4 (Xaa and Yaa) are of varied structure 
and therefore responsible for this great diversity, while the other positions are more 
conserved (Figure 3.2).[11]  
 
 
 
 
 
 
 
Figure 3.2. General structure of microcystin (Yaa and Xaa represent variable amino acids) 
 
Adda is the unusual amino acid 3-amino-9-methoxy-2,6,8-trimenthyl-10-
phenyl-4,6-decadienoic acid, D-MeAsp represent the 3-methylaspartic acid and Mdha 
is N-methyldehydroalanine. Other variable groups in microcystins are the Dha, which 
is sometimes methylated (Mdha) like in microcystin-LR (MC-LR) or substituted by a 
threonine derivative (2-amino-2-butenoic acid, Dhb) or replaced by a native serine.[12] 
Furthermore, variations in the Adda side chain are possible, like acetylation or 
removal of the O-methyl group.[13] 
The name of this toxin class is derived from first poisonous compound isolated 
from Microcystis aeruginosa.[14] Additionally, the precise name of the microcystin 
isoforms are determined by the two highly variable amino acids Xaa and Yaa, e.g. 
microcystin-LR (MC-LR) where Xaa = Leu at position 2, and Yaa = Arg at position 4 
(Figure 3.3).  
 
 
 
 
 
 
 
 
Figure 3.3. Structure of MC-LR 
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The synthesis of the different toxins takes place outside the ribosome 
(non-ribosomally) in an enzyme complex that includes peptide synthetases, 
polyketide synthases and other enzymes.[15,16] A 55 kb gene cluster, possessing two 
putative operons (mcyA-C and mcyD-J) is responsible for the MC-production, 
whereas for the activation and incorporation of Mdha, D-Ala, L-Xaa, D-MeAsp and 
L-Yaa the genes mcyA, mcyB, and McyC are reported to be in charge.[17,18] In this 
way, it is possible for different cyanobacteria strains to produce several diverse 
microcystins in parallel.[8] Within this toxin class, MC-LR is the most extensively 
studied microcystin due to its high LD50 value (50 !gkg-1 in rats).[19] The fact that the 
World Health Organization (WHO) has set a maximal guideline value of 1 !gL-1 
MC-LR in drinking water further emphasize its potency and toxicity.[20,21] In humans, 
this substances shows a hepatotoxic effect through inhibition of protein 
phosphatases 1 (PP1) and 2A (PP2A) and the chronic exposure can cause liver 
cancer.[6,7,23] It also causes a disruption of the cytoskeletal components accompanied 
by cell deformation initiated by cytokeratin hyperphosphorylation, which ends in a 
collapse of the whole liver architecture.[24] Moreover, MC-LR seems to cause 
DNA-damage, apoptosis, disruption in the cell-signalling and endoplasmic reticulum 
stress.[25-27] The known transport of MCs in the cell is the organic anion polypeptide 
transporter (OATP), e.g. in human hepatocytes.[28,29] In aquatic organisms, which are 
particularly vulnerable to cyanobacterial microcystins due to the increased levels of 
exposure, such toxic effects are also displayed. For example, in Daphnia magna, 
which is an important grazer of algae as a food source, disturbance in the 
reproduction together with higher mortality rates and deteriorated development are 
observed.[1,10,30-32] In fish and invertebrates, the toxin accumulates in the tissues and 
leads to a number of toxic effects.[11,33] 
Even though microcystins have been known for decades, the reasons for the 
strong toxicity in animals are not yet fully understood. To gain an insight into the 
uptake, distribution, accumulation and excretion of MC-LR, biological studies are 
necessary. The main goal of this project was the synthesis of fluorescently labelled 
MC-LR in order to monitor its behaviour as mode of action, uptake and excretion in 
aquatic animals. It was crucial to synthetically modify the molecule for these studies 
without inactivating its toxicity effect. That necessitated an investigation of the 
structural elements involved in the enzyme binding.  
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It has beed reported that the reactive Mdha groups binds in a Michael-type 
addition covalently to Cys 273 of the phosphate 1 and the Adda side chain interacts 
with the hydrophobic cage of the active pocket.[34] Furthermore, the crystal structure 
of the MC-LR/PP1 complex shows that leucine and the carboxylate groups are also 
involved in enzyme binding.[22] But interestingly, it also reveals, as the arginine 
function sticks out of the binding pocket (see arrow), that this residue is not 
participating in the inhibition of the phosphatase 1 and, thus, presents a promising 
site for modification (Figure 3.4).[22]  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Structure of the catalytic domain of phosphatase 1" with MC-LR[22]  
 
Nevertheless, efficient acetylation of the arginine guanidine group had proved 
to be difficult due to the high pKa value of this protonated side chain (pKa = 12.5). 
Shreder and co-workers have successfully introduced a fluorophore at this moiety in 
MC-LR with a compromised yield by using a two-step procedure.[35] Similar yields 
were obtained by a comparable reaction to a MC-LR-DNA conjugate.[36] In 
consideration of the limited availability of the toxin, further methods are needed to 
modify MC-LR. In this work, we describe the development of a facile labelling 
procedure of MC-LR. In addition, we test our derivatives with regard to remaining 
toxicity compared to the parent compound. 
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3.2 Results and discussion 
3.2.1 Synthesis of the modified MC-LR 
 
As already discussed, modification of the arginine residue should not affect the 
enzyme binding as suggested by the crystal structure.[22] Furthermore, 
hypervariations in the amino acid sequence at this position in natural occurring 
microcystins support the assumption that this residue is not important for the 
inhibitory effect.  
To find an effective labelling method for MC-LR, we had to consider several 
difficulties: (a) The poor reactivity of the guanidinium group, (b) MC-LR contains other 
reactive groups like the reactive unsaturated Mdha residue, (c) MC-LR gets 
degraded under strong basic or acidic conditions, and (d) the availability of the toxin, 
which can only be isolated on a microgram scale.[37] 
Thus, different strategies for labelling this moiety has to be investigated. 
Different promising conditions described in chapter 2 were tested with MC-LR in 
parallel, to identify the best labelling strategy. Furthermore, to examine the behaviour 
of the sensitive groups and to monitor possible side reactions in MC-LR, the 
optimized conditions were first tested with Boc-Asp and Z-dehydro-Ala-OH together 
with Bz-Arg-OEt.  
The first modification on MC-LR was carried out with dansyl chloride (1.5 eq.) 
with NEt3 in DMF. The high reactivity of dansyl chloride was presumed to be 
problematic due to the small size of the compound. We then moved to a more bulky 
sulfonyl chloride reagent. To this extent, lissamine rhodamine B (1.5 eq.) was used. 
This reaction was not showing conversion to the desired product, but gave a complex 
mixture. A solvent change to dioxane was also not leading to success. We then 
decided to apply a method known to label amines in an efficient manner.[38]  
For this matter we performed the coupling with N-hydroxysucinimide (2 eq.), 
EDC (2 eq.), rhodamine B (2 eq.) and NEt3 (10 eq.) in MeCN. The use of NEt3 did not 
led to the desired compound. We next sought to simplify the setup. Subsequently, 
Alexa fluor555 succinimide (2 eq.), DBU (12 eq.) in DMF was used. Unfortunately, 
this also did not leading to the desired conversion. Similarly, the use of NEt3 showed 
no product formation. Another drawback of the above-mentioned conditions was that 
MC-LR degraded and could not be recovered. For this reason we focused on mild 
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reaction conditions to identify a base strong enough to deprotonate the guanidinium 
group, without degrading the MC-LR. 
We therefore studied the use of Barton`s base (see also chapter2). The 
coupling of MC-LR was performed according to the standardized protocol at 40 °C 
dissolving the toxin in DMF and adding Barton’s base. After initial stirring and 
subsequent addition of the dissolved activated ester, the reaction was stirred for eight 
hours. To our delight, the desired coupled product was obtained in moderate to good 
yields (35 % to 84 %). Interestingly, an “one shot” purification by HPLC could double 
the yield, compared to the multistep purification. The reason for that is probably the 
loss of material on the needlepoint of the HPLC. Utilizing this method, we 
synthesized four fluorescently labelled derivatives, as well as a biotin and a diazirine 
conjugates (Figure 3.5, 3.6 and 3.7). A proton NMR of 3.1 could be measured, 
however, an assignment of the signals was difficult due to the complexity of the 
molecule. MS-MS studies were performed to confirm the formation of the correct 
product. We identified the labelled Arg moiety of the MC-LR-(6-FAM) and the 
MC-LR-(Texas-Red) conjugate, however for MC-LR-(Alexa-430), we could not 
entirely exclude modification of the Glu or MeAsp side chains. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Synthesized derivatives of MC-LR  
MC-LR coupled with carboxyfluorescein (3.1) 
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Figure 3.6. Synthesized derivatives of MC-LR  
MC-LR coupled with Alexa-430 (3.2), Alexa-488 (3.3) and Texas Red (3.3) 
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Figure 3.7. Synthesized derivatives of MC-LR  
MC-LR coupled with biotin (3.5) or diazirine (3.6) 
 
 
3.2.2 Photochemical properties of MC-LR-(6-FAM), MC-LR-(Alexa-430) and MC-LR-
(Texas-Red) 
 
After successfully labelling of MC-LR with different fluorophores, we investigated the 
photochemical properties of compounds 3.1, 3.2 or 3.4. We anticipated that these 
derivatives could be used in further biological tests. The fluorescent spectrum of 3.1, 
3.2, or 3.4 is shown in Figure 3.8 The maximum absorption of the derivatives was at 
499 nm for MC-LR-(6-FAM), at 425 nm for MC-LR-(Alexa-430) and at 586 for 
MC-LR-(Texas-Red). Furthermore, the maximum emission is located at 525 nm for 
MC-LR-(6-FAM), at 434 nm for MC-LR-(Alexa-430) and at 605 nm for 
MC-LR-(Texas-Red). With this data, we were able to choose the right compounds for 
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the various uptake studies, with regards to overlapping with intrinsic fluorescence of 
the used chemicals and test systems. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Spectral profile  
A: MC-LR-(6-FAM) B: MC-LR-(Alexa-430) C: MC-LR-(Texas-Red) 
 
To visualize the spectral colour of the different compounds, the colour space 
chromaticity diagrams are shown in Figure 3.9. MC-LR-(6-FAM) is located more in 
the yellowish-green range (x: 0.32 y: 0.66), whereas MC-LR-(Alexa-430) is already in 
the yellow-green area (x: 0.38 y: 0.58) and MC-LR-(Texas-Red) is situated in the 
orange-yellow section (x: 0.65 y: 0.36). 
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Figure 3.9. CIE colour space chromaticity diagram and fluorescent picture 
A: CIE colour space chromaticity diagram of MC-LR-(6-FAM) B: Fluorescent picture of 
MC-LR-(6-FAM)  
C: CIE colour space chromaticity diagram of MC-LR-(Alexa-430) D: Fluorescent picture of 
MC-LR-(Alexa-430)  
E: CIE colour space chromaticity diagram of MC-LR-(Texas-Red) F: Fluorescent picture of 
MC-LR-(Texas-Red) 
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In addition, the quantum yield of compounds 3.1, 3.2 or 3.4 was determined as 
an important parameter for the fluorescence intensity at the minimum concentration 
for biological experiments. The following values were obtained: MC-LR-(6-FAM) 
# = 0.66 (Ex: 503 nm); MC-LR-(Alexa-430) # = 0.57 (Ex: 450 nm); 
MC-LR-(Texas-Red) # = 0.88 (Ex: 546). The Texas-Red derivative is the best choice 
for large dilutions as its quantum yield of 0.88 allowing high enough sensitivity for the 
following measurements. 
 
3.2.3 Comparison of biological activities of native MC-LR and modified MC-LR  
 
With the derivatives in hand, we were ready to investigate whether the prepared 
compounds had retained biological activity for the parent species.! We performed 
selected bioassays with the MC-LR derivatives. Afterwards, we compared the results 
to known literature values of MC-LR to identify if the derivatives retained their toxicity. 
First, we used phosphatase inhibition assays to examine the differences in inhibition 
activity of the derivatized MC-LR in comparison to the native MC-LR towards the 
phosphatase 2A, one of its primary targets. In addition, we tested the ability of the 
derivatives to induce ER-stress. We then examined the cellular uptake of the MC-LR 
derivatives and performed cell viability assays in Huh 7 liver cells.!Next, we analysed 
the toxicity of the modified compounds toward aquatic organisms! to verify that the 
toxin remains toxic in the living organism. The uptake of the labelled MC-LR 
derivatives was imaged in uptake studies with adult Daphnia galeata and Daphnia 
magna.  
 
3.2.3.1 Phosphatase inhibition assays 
 
The inhibitory effect of labelled MC-LR in comparison to unlabelled MC-LR was 
tested against PP2A. The primary tests showed that the fluorophores themselves 
were not interfering with the absorbance and the emission of the substrate, which 
allowed the use of compound 3.1 and 3.2 in the inhibition assays as test substrates. 
These derivatives were chosen to investigate, if a negative charge in the compounds 
has a different influence on the inhibitory activity. For this the PP2A was incubated 
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with the toxin in different concentrations (0.004 nM up to 40 nM) and 6,8-difluoro-4-
methylumbelliferyl phosphate (DiFMUP). The activity of the non-inhibited PP2A 
enzyme reaction is associated with the measured fluorescence of released 
6,8-difluoro-4-methylumbelliferone. 
 
 
 
Figure 3.10. Phosphatase inhibition assay  
A: with MC-LR-(6-FAM) IC50 = 0.37 nM B: with MC-LR-(Alexa-430) IC50 = 0.61 nM 
 
The data showed that MC-LR-(6-FAM) with an IC50 value of 0.37 nM inhibits 
PP2A much stronger than MC-LR-(Alexa-430) with an IC50 value of 0.61 nM 
respectively (Figure 3.10). In comparison with MC-LR itself, having an IC50 value of 
0.05 nM, both compounds inhibit the enzyme to a lesser extent.[39] Although the 
inhibition is seven to twelve times weaker than the inhibition of MC-LR itself, the 
compounds have not completely lost their toxicity. Possibly, the size (1.5 times more 
than that of MC-LR) of the molecules and the proximity of the fluorophore to the Adda 
side chain might have an influence on their binding and inhibition activity.[40] The 
difference in the inhibition ability of the two compounds could be explained by the 
negative charge of the MC-LR-(Alexa-430) derivative. The sulphate moiety of the 
fluorophore could interact with the metal site of the enzyme and thus competes with 
the binding of the glutamate to the latter.[22] In this way the positioning of the toxin in 
the binding pocket would be altered, therefore hindering the efficient binding or 
significantly slowing down the process of covalently attaching of the Mdha residue.[41]  
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3.2.3.2 RNA isolation, reverse transcription and quantitative (q)PCR for ER-stress 
response 
  
To investigate the ability of the derivatives to induce ER-stress response, we 
performed quantitative (q)PCR measurements with the key ER-stress marker BiP 
and an internal control (GAPDH). In order to do that, we incubated Huh7 cells with 
5 !M and 50 !M of MC-LR-(Alexa-430) over 24 h. DNA was obtained from isolated 
RNA using reverse transcription. The qPCR showed an upregulation of BiP 
(Figure 3.11).  
 
 
 
 
 
 
 
 
 
 
Figure 3.11. Induction of ER-stress  
Huh7 cells after exposure of MC-LR-(Alexa-430), expression of BiP after 24 h 
 
This induction of the chaperon BiP suggests that the derivative is still causing 
ER-stress. However, we did not observe this tendency in follow up studies. An 
explanation for that could be that the toxicity of the compound is higher than the 
parent compound and the cells were already dead after a short incubation time. The 
RNA started to degrade before measurements of the ER-induction could be obtained. 
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3.2.3.3 MTT assay for cytotoxicity 
 
To examine the cellular uptake and the toxicity of the MC-LR derivatives, MTT 
cytotoxicity assays for cell viability were performed. Huh 7 cells were incubated with 
different concentrations of compound 3.2 for 24 h. Additionally fluorescent imaging of 
the cells was performed after 4 h to visualize the uptake of the labelled toxin. 
Cytotoxicity was validated with MTT assays. In comparison to MC-LR (4.3 !M[25]) an 
EC50 value of 16.3 !M for compound 3.2 was measured (Figure 3.12). The EC50 
value of MC-LR-(Alexa-430) is four times higher than the parent compound. This is 
maybe due to the negative charge of the derivative as described before. 
 
 
 
 
 
 
 
 
 
Figure 3.12. Cell viability assay  
A: with MC-LR-(Alexa-430), EC50 = 16.3 !M B: with hydrolysed Alexa-430  
 
Interestingly, the inhibition behaviour of the phosphatase 2A seemed to be 
more affected by the derivatization than the cell uptake. This can either be due to the 
longer time of the experiment as well as the longer incubation time, whereas eventual 
binding problems can be overcome. This result could also be explained with the 
assumption, that the transporters responsible for MC-LR uptake, the OATPs, are 
suited for negatively charged compounds.[42]  
Furthermore, visualization of the treated cells revealed that the toxin is present 
in the cells (Figure 3.13). Additionally, the control picture of the hydrolysed 
fluorophores showed that the fluorophore itself couldn’t be taken up into the cells. 
This also revealed that the fluorescent MC-LR derivative is not hydrolysed under the 
conditions of the assay. Therefore, compound 3.2 demonstrated efficient cell uptake 
with retained cytotoxicity. 
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Figure 3.13. Fluorescent imaging of Huh 7 liver cells  
A: Fluorescent image at 100 !M with MC-LR-(Alexa-430) B: Phase Contrast at 100 !M with 
MC-LR-(Alexa-430)  C: Fluorescent image at 12.5 !M with MC-LR-(Alexa-430) D: Phase 
Contrast at 12.5 !M with MC-LR-(Alexa-430) E: Fluorescent image at 100 !M with hydrolysed 
Alexa-430 D: Phase Contrast at 100 !M hydrolysed Alexa-430 
 
3.2.3.4 Acute toxicity assay 
 
We analysed the toxicity of the modified compounds towards aquatic organisms. The 
freshwater crustacean Thamnocephalus platyurus was chosen for the acute toxicity 
test, as it is a widely used system for such cyanotoxin toxicity assessment.[43] As test 
substrates we took derivatives 3.1 and 3.2. We administered these compounds over 
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24 h, to determine the LC50 value compared to unlabelled MC-LR. With an LC50 value 
of 5.7 !M for 3.1 and 15.7 µM for 3.2, the test revealed toxicity towards aquatic 
organisms comparable to MC-LR (10.8 µM)[39] (Figure 3.14). This implied that the 
functional tag is not interfering with the mode of action of the toxin. 
 
 
Figure 3.14. Acute toxicity assay  
A: with MC-LR-(6-FAM), LC50 = 5.7 !M B: with MC-LR-(Alexa-430), LC50 = 15.7 !M 
 
Fluorescent imaging of animals treated with MC-LR-(Alexa-430) was revealed 
that the compound was only accumulated in the digestive track (Figure 3.15).[44]  
 
 
 
 
 
 
 
Figure 3.15. Fluorescent imaging of MC-LR-(Alexa-430) treated Thamnocephalus platyurus 
A: Fluorescent image at 100 !M with MC-LR-(Alexa-430) B: Phase Contrast at 100 !M with 
MC-LR-(Alexa-430)   
 
Interestingly, the MC-LR-(6-FAM) derivative has a better inhibition behaviour 
than MC-LR-(Alexa-430). It suggests that the negative charge indeed hinders the 
activity of the toxin. Another difference is, that the toxicity is not as much decreases 
as the inhibitory effect. This can be explained with the time difference of the 
experiments. It is possible, that the process of inactivation of important enzymes by 
the modified MC-LR is completed after 24 h, whereas the inhibition of the 
phosphatase 2A is still continuing after 10 min.!
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3.2.3.5 Uptake studies in Daphnia galeata and Daphnia magna  
 
The uptake of the labelled MC-LR derivatives was traced in studies with adult 
Daphnia galeata and Daphnia magna. The microscopic investigation of Daphnia 
galeata showed compound 3.2 not only distributed in the gastrointestinal tract, but 
also in another area which is not accessible to food, in this case the cecum, which is 
separated from the gut by a membrane (Figure 3.16).  
 
 
 
 
 
 
 
Figure 3.16. Fluorescent imaging of Daphnia galeata 
Exposure of Daphnia galeata to 3.1 after 3 h; Compound 3.1 accumulates in the cecum 
(arrow) 
 
To examine the uptake behaviour in an extended time range, uptake studies 
with Daphnia magna were performed over 72 h. Different points in time were taken to 
monitor the distribution of the toxin. The toxin was also accumulating in the 
gastrointestinal tract and the cecum after a short time period. The same distribution is 
observed over time, whereas after 72 h an accumulation in the cecum could only be 
observed in smaller concentrations of compound 3.1.  
 
 
 
 
 
 
 
 
Figure 3.17. Fluorescent imaging of Daphnia magna  
Exposure of Daphnia magna to 3.1 after 72 h; Compound 3.1 accumulates in the cecum  
!!
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3.3 Conclusion 
 
In conclusion, we have successfully developed a mild and operatively simple 
derivatization method for MC-LR in moderate to good yield. This method allows the 
modification of the toxin with a variety of biologically important tags, such as 
fluorescent labels, diazirine and biotin tags. Furthermore, we demonstrated that the 
MC-LR derivative remains active towards one of the primary target, the enzyme 
phosphatase 2A (IC50 value of 0.37 nM) and is active towards aquatic organisms 
(LC50 value of 5.7 µM). In addition, the tagged MC-LR successfully undergoes 
cellular uptake by Huh 7 cells and retains toxicity (EC50 value of 4.3 !M). The 
compound uptake in an in vivo system was also performed with Daphnia galeata and 
Daphnia magna, where it remains not only in the digestive tract, but also penetrates 
the membrane barrier into the cecum.! Additional ongoing studies aim to investigate 
the uptake of the labelled MC-LR derivatives in parental Daphnia magna, as MC-LR 
is known to affect reproduction.  
!!
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3.4 Methods 
3.4.1 General  
 
The following reagents were purchased and used as received: NHS-diazirine 
(Thermo Scientific), all reactive succinimidyl ester fluorophores (Invitrogen), 
Seaplaque agarose (Lonza), all further chemicals were purchased from 
Sigma-Aldrich Co. and were of analytical grade. Biotin p-nitrophenylester was kindly 
provided by K. Tishinov (Universit of Basel); Microcystin-LR was isolated or provided 
by E. Kohler or purchased from Enzo Life Sciences. Thamnocephalus platyurus for 
the acute toxicity assay were purchased from MicroBioTests Inc., Belgium. The 
PP2A enzyme was purchases from Promega, USA. 6,8-difluoro-4-methylumbelliferyl 
phosphate was received from Molecular Probes, Leiden, The Netherlands. HuH7 
cells were provided by Susanne Faltermann (University of Applied Sciences and Arts 
Northwestern Switzerland).  
For measuring the fluorescence in the protease inhibition assays a fluorescence 
microplate reader (Spectra MAX gemini XS; Molecular Devices Cooperation, 
Sunnyvale, California, USA) was used set at lem = 365 nm, lex = 444 nm. All reactions 
were carried out in oven-dried glassware under an atmosphere of argon. HPLC 
purifications of the functionalized MC-LR was obtained on a Dionex P-680 HPLC 
System with a Phenomenex Gemini C18 5 µ (250 mm x 4.6 mm) column or a 
Phenomenex Gemini C18 5 µ (150 mm x 4.6 mm) column using a linear gradient: 5 
% to 100 % CH3CN in 0.1 % Formic acid/H2O over 40 minutes at a flow rate of 
1 mL/min. For removal of the formic acid a final purification step was performed on a 
C18 SPE cartridge (500 mg, Supelco) starting with a first washing step with water to 
remove the acid and a final elution step with 80 % acetonitrile.  
The yield of modified MC-LR was determined using a NanoDrop 2000 
Spectrophotometer (Thermo scientific). UV-Vis data was recorded on an Agilent 
8453 spectrophotometer, the fluorescence was measured on a Fluorimeter: 
Shimadzu 5301PC spectrofluorophotometer and the quantum yield was determined 
on a Hamamatsu absolute PL quantum yield spectrometer C11347 Quantaurus_QY. 
1H-NMR spectrum was recorded on a Bruker Avance III Ultrashield 600MHz with a 
5mm BBFO+ plus SP probe or a Bruker Avance III Ascend 700MHz with a 5mm TCI 
(H-C/N-D) cryo probe spectrometers at room temperature. HRMS spectra were 
recorded on a Bruker maXis 4G instrument or measured by the mass spectrometric 
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service of University of Bern on a Sciex QSTAR Pulsar mass spectrometer. HRMS 
spectra were obtained on a Bruker maXis 4G with ESI in positive or negative mode. 
MS-MS experiments were obtained on a Bruker Esquire 3000 with ESI in positive 
mode. 
 
3.4.2 Cell culturing, extraction and isolation 
 
M. aeruginosa UV-006 was cultivated in 500 mL Falcon tubes in 200 mL mineral 
medium at 25 °C with 12h light and night cycle.[45] The resulting biomass was 
harvested every three months with a 6K15 centrifuge (Sigma), freezed and stored at 
-20 °C. To obtain pure MC-LR the cyanobacteria were suspended in 20 mL of 60 % 
acetonitrile per 1 g biomass and sonicated for 10 min (Branson 2510). The resulting 
homogenous mixture was centrifuged for 15 min at 25000 x g and the supernatants 
were combined and evaporated in a rotarory evaporator (Büchi, Switzerland). The 
residue was dissolved in 60 % acetonitrile and prepurified on a C18 SPE cartridge 
(10 g, Supelco). The crude mixture was eluted with 80 % acetonitrile (500 mg 
biomass afforded 15 mg crude extract), concentrated and applied on a Dionex P-680 
HPLC System with a Phenomenex Gemini-NX C18 5µ (75 mm x 21.2 mm) column 
using a linear gradient: 5 % to 100 % CH3CN in 0.1 % Formic acid/H2O over 
40 minutes at a flow rate of 5 mL/min for further purification. For removal of the 
formic acid a final purification step was performed on a C18 SPE cartridge (500 mg, 
Supelco) starting with a first washing step with water to remove the acid and a final 
elution step with 80 % acetonitrile. After removal of all volatiles and lyophilisation 
pure MC-LR (600 !g from 15 mg crude extract) was afforded as a white solid. HPLC: 
tR = 18.1 min; MS (ESI): m/z = 995.9 [M+H]+ 
 
3.4.3 Synthesis of the modified MC-LR 
3.4.3.1 General procedure for the functionalization MC-LR 
 
To a solution of MC-LR (1 eq.) in DMF (50 µl) were added Barton’s base (10 eq.) and 
the activated ester (1.5,1.1 or 4 eq.) in DMF (20 µl). The resulting mixture was stirred 
at 40 °C for 8h. All volatiles were removed under reduced pressure and the residue 
was purified by HPLC.  
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MC-LR-(6-FAM), (3.1): 
According to the general procedure compound 3.1 was synthesized starting from 
MC-LR (0.40 mg, 0.40 µmol). Barton’s base (0.70 mg, 4.09 µmol) and 
5(6)-carboxyfluorescein N-succinimidyl ester (0.22 mg, 0.46 µmol) were used. Direct 
purification by HPLC afforded 3.1 (423 µg, 0.31 µmol, 84 %) as a red solid. HPLC: 
tR = 23.6 min; HRMS-ESI: calcd. for C70H85N10O18+ [M+H]+: 1353.6038; found: 
1353.6087. 
 
 
MC-LR-(Alexa-430), (3.2):  
According to the general procedure compound 3.2 was synthesized starting from 
MC-LR (1.00 mg, 1.00 µmol). Barton’s base (1.10 mg, 6.43 µmol) and Alexa 430 
succinimidyl ester (0.78 mg, 1.11 µmol) were used. Direct purification by HPLC 
afforded 3.2 (1.36 mg, 0.92 µmol, 74 %) as a red solid. HPLC: tR = 33.4 min; 
HRMS-ESI: calcd. for C71H95N11O18F3S- [M-H]-: 1478.6524; found: 1478.6527. 
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MC-LR-(Alexa-488), (3.3):  
According to the general procedure compound 3.3 was synthesized starting from 
MC-LR (0.20 mg, 0.20 µmol). Barton’s base (0.34 mg, 2.0 µmol) and Alexa 488 
5-sulfodichlorphenol ester (0.25 mg, 0.30 µmol) were used. Direct purification by 
HPLC afforded 3.3 (0.17 mg, 0.11 µmol, 55 %) as a red solid. HPLC: tR = 10.9 min; 
HRMS-ESI: calcd. for C70H84N12O22S22- [M-H-H]2-: 754.2638; found: 754.2625. 
 
 
 
MC-LR-(Texas-Red), (3.4):  
According to the general procedure compound 3.4 was synthesized starting from 
MC-LR (0.50 mg, 0.50 µmol). Barton’s base (0.86 mg, 5.02 µmol) and Texas Red 
succinimidyl ester (0.50 mg, 0.61 µmol) were used. Direct purification by HPLC 
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afforded 3.4 (650 µg, 0.38 µmol, 76 %) as a red solid. HPLC: tR1 = 23.6 min; 
tR2 = 25.6 min; HRMS-ESI: calcd. for C86H114N13O19S2Na2+ [M+H+Na]2+: 859.8841; 
found: 859.8852. 
 
 
 
 
MC-LR-(Biotin), (3.5):  
According to the general procedure compound 3.5 was synthesized starting from 
MC-LR (0.10 mg, 0.10 µmol). Barton’s base (0.20 mg, 1.0 µmol) and 
p-nitrophenylester (40 µg, 0.11 µmol) were used. Direct purification by HPLC using 
first the gradient from the general procedure and for further purification 50 % CH3CN 
in 0.1 % Formic acid/H2O with isocratic conditions afforded 3.5 (46 µg, 0.038 µmol, 
37 %) as a red solid. HPLC: tR = 19.9 min (gradient); tR = 8.5 min (isocratic); 
HRMS-ESI: calcd. for C59H89N12O14S+ [M+H]+: 1221.6336; found: 1221.6340. 
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MC-LR-(DA), (3.6):  
According to the general procedure compound 3.6 was synthesized starting from 
MC-LR (0.10 mg, 0.10 µmol). Barton’s base (0.20 mg, 1.0 µmol) and 
succinimidyl-diazirine (90 µg, 0.40 µmol) were used. Direct purification by HPLC 
afforded 3.6 (39 µg, 0.035 µmol, 35 %) as a red solid. HPLC: tR = 21.8 min; 
HRMS-ESI: calcd. for C54H81N12O13+ [M+H]+: 1105.6041; found: 1105.6039. 
3.4.4 Phosphatase inhibition assays 
 
The enzyme mixture was prepared as followed: 2 µl of the PP2A enzyme were 
dissolved in 650 µl EGTA (1 mM), 50 µl DTT (10 mM in 5 mM sodium acetate 
pH = 5.2), 200 µl MnCl2 (6 mM) and 100 µl BSA (5 mg/mL). The reaction buffer was 
prepared out of 290 µl MnCl2 (6 mM), 290 µl MgCl2 (0.8 M) and 290 µl BSA 
(5 mg/mL). In a 200 µl well plate 25 µl of the enzyme mixture was used. To achieve a 
final concentration of 25 mU PP2A/200 µl, 30 µl Tris-HCl (50 mM, pH = 7.0) and 15 µl 
of the reaction buffer were added. The mixture was incubated for 10 minutes at 
37 °C. Afterwards 10 µl of 3.1 and 3.2 were added in various concentrations 
(0.004 nM up to 40 nM). Only the fluorophores were used as control experiment to 
test possible interference with the experimental setup. Subsequent incubation at 
37 °C for 10 minutes was followed. To start the measurement 120 µl of 6,8-difluoro-
4-methylumbelliferyl phosphate (10 mM dissolved in 50 mM Tris-HCl pH = 7.0) 
solution were added. After a final incubation over 5 minutes at 37 °C the fluorescence 
measurement was started by taking a data point every 30 seconds for 45 minutes. To 
obtain the activity of the phosphatase, linear regression was used using Graph Pad 
Prism 4.1 for Windows.  
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3.4.5 RNA isolation, reverse transcription and quantitative (q)PCR for ER-stress 
response 
 
Huh7 cells were plated at a density of 50000 cells per condition in 50 µl fractions in a 
96-well plate with DMEM and GlutaMAX with 10 % FBS. After 24 h in a humidified 
incubator (5 % CO2, 37 °C) different dilutions of compound 3.2 was added to the 
cells. After additional 24h the medium was removed and the RNA was isolated with 
Trizol reagent (LuBioScience) from the Huh7. Reverse transcription of the RNA was 
performed by the Moloney murine leukemia virus reverse transcriptase (Promega), 
random hexamers (Roche) and deoxynucleoside triphosphate. After incubation for 
5 min at 70 °C, followed by an incubation over 1 h at 37 °C, the reaction was heated 
up to 95 °C for additional 5 min. qPCR was carried out with SYBR green (Roche) and 
with the primers for BiP (forward CGAGGAGGAGGACAAGAAGG; reverse 
CACCTTGAACGGCAAGAACT). The PCR cycle (BioRAD CFX 96 Real Time 
System) started with 95 °C for 5 min and continued with 40 cycles of 95 °C for 30 s 
and 60 °C for 60 s. Subsequently a melting curve was run. The cycle threshold value 
was determined by subtracting the value of the internal control GAPDH from the 
value of the target genes. The expression level of the mRNA was calculated 
afterwards according to the formula 2^(DCT untreated – DCT treated).  
 
3.4.6 MTT assay for cytotoxicity 
 
Huh7 cells were plated after growing in DMEM containing GlutaMAX (LuBioSciene) 
with 10 % FBS in a humidified incubator (5 % CO2, 37 °C), in a 96-well plate at a 
density of 50000 cells per condition in 50 µl fractions. After 24 h of incubation, a 
series of diluted solution of compound 3.2 was added to the cells. After additional 
24 h, the mixture was replaced with 200 µl fresh medium. Pictures of the uptake into 
the cells were taken with an Olympus CKX41 biological microscope with a 10x 
objective. Analysis of the pictures were performed with Cell B Version 3.2. Afterwards 
20 µl of MTT (5mg/mL) was added, followed by an incubation over 2 h at 37 °C. 
Subsequently, the solution was removed and 200 µl DMSO was added and mixture 
was shaken for 15 min and cytotoxicity was measured.  
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3.4.7 Acute toxicity assay 
 
To determine the acute toxicity of the modified MC-LR, compound 3.1 and 3.2 was 
utilized in an acute toxicity assay with Thamnocephalus platyurus in a multiwell plate 
using instar II-III larvae hatched from cysts during 24 hours. Compounds 3.1 and 3.2 
were tested in various concentrations (0.5 to 100 µM) using 30 animals per condition. 
The LC50 value was calculated using the nonlinear regression Graph Pad Prism 4.1 
for Windows was used. 
 
3.4.8 Uptake studies in Daphnia galeata and Daphnia magna  
 
Adult Daphnia galeata were exposed to 50 !M of compound 3.1 over 4 h at room 
temperature. In the next experiment Daphnia magna were placed in a 24-well-plate 
containing 1 mL of the labelled toxin. After 4 h the animals were rinsed with water 
and monitored with a Zeiss Axio Imager M1 microscope, equipped with a NIKON 
EOS 1000D camera. As contrast differential interference with an objective 10 x was 
used. Analysis of the images were performed with AxioVision 4.8.2. 
Further uptake studies were performed in Daphnia magna. 48 h old Daphnia magna 
were exposed to 10 !M, 1 !M and 0.01 !M solution of compound 3.1 at 20 °C. 10 
animals were placed in a 50 mL baker containing 15 mL of the test solution in M4 
medium without food additions. The experiment was performed over 72 h, whereas 
after 3 h, 6 h, 24 h, 48 h and 72 h samples were taken. For this the Daphnia were 
rinsed with fresh medium and immobilized with 1 % agarose gel. The uptake of the 
fluorescent labelled compound 3.1 was followed on a Olympus Fluoview FV1000 
confocal laser scanning biological microscope with a 4x objective. The excitation was 
performed at 488 nm with 15 % laser transmission. The analyses of the pictures was 
carried out with FV 10-ASW Version 03.00.02.00.  
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4.1 Introduction 
 
Cyanobacteria produce various toxins with a great diversity for the different 
compound classes, whereby the majority are peptides or contain a peptide-like 
structure. Every year, new compounds are isolated and new biological activities are 
discovered. Some of the most potent toxins produced by cyanobacteria are the 
microcystins, which is one reason for the high attention for microcystin-producing 
organisms and therefore toxic cyanobacteria. The common genetic background of 
these species is the myc gene cluster, which is responsible for the toxin production.[1] 
The main purpose of the production of various microcystins is not clear yet, whereas 
an evolutionary protection against grazers and so also a biological advantage against 
non microcystin-producing cyanobacteria is likely. However, it was found, that 
Planktothrix with inactive myc gene cluster shows no disadvantages of growth in 
contrast to microcystin-producing strains. Another possibility is yet unknown peptides 
or group of peptides replacing microcystin in its biological role.[2] 
In this regard, our cooperation partner (Esther Kohler, University of Zurich) 
examined, with HPLC-guided fractionation, the activity of six different Planktothrix 
strains against Thamnocephalus platyurus and detected an unknown chlorinated and 
sulphated toxic peptide. This toxin appeared to be from the aeruginosin family, as 
judged from its retention time, spectral properties and the preliminary 
MS-experiments. 
Aeruginosins are produced by the cyanobacterial genus Microcystis and 
Planktothrix.[3] Aeruginosins show a great structural variety due to their synthesis 
through the NRPS pathway, as post-translational modification with sugar moieties, 
chlorine or sulphate substituents is also possible.[3,4] At the moment, more than 40 
variants of this compound class are known, with the characteristic core structure 
containing the unusual amino acid 2-carboxy-6-hydroxyoctahydroindole (Choi) and 
hydroxyphenyllactic acid (Hpla) or lactic acid (Pla). In addition, the aeruginosins 
contain a variable hydrophobic amino acid (Leu, Ile, Phe, or Tyr) and an arginine 
derivative (Figure 4.1).[5]  
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Figure 4.1. General structure of Aeruginosin  
 
Characteristic for this class is its ability to inhibit trypsin-like serine proteases, 
especially trypsin and thrombin.[6-8] This is due to its high affinity for the catalytic 
pocket of the protease. Since thrombin participates in the blood coagulation cascade, 
aeruginosins might be used for treatment of thrombotic disorders.[9] Furthermore, 
certain compounds from that group show inhibitory activity against other proteases 
like papain.[9] Additionally, compounds with new biological activity are constantly 
isolated, like aerguniosin-865. This compound, containing for the first time an uronic 
acid and a fatty acid moiety, shows anti inflammatory activity through inhibition of the 
translocation of NF-!B to the cell nucleus.[10] Despite of this inhibition ability, no 
toxicity is so far linked to this compound class. This work discusses the structure 
elucidation of a newly isolated unknown chlorine and sulphate-containing 
aeruginosin.  
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4.2 Results and discussion 
 
Our cooperation partner, Esther Kohler (University of Zurich), analysed the toxicity of 
six Plankthothrix strains. For that purpose, methanolic extractions of the 
cyanobacterial biomass followed by HPLC-guided fractionation was performed. The 
toxicity of these fractions was evaluated with acute toxicity assays against the 
crustacean Thamnocephalus platyurus. Further fractionation and toxicity screening 
lowered the number of highly toxic fractions down to twelve. Final investigations 
revealed the presence of three already known microcystins, seven unknown 
sulphated cyanopepotlins and ten sulphate and chlorine-containing aeruginosins. 
Interestingly, the last compound class associated with high toxicity, could only be 
found in four non- microcystin-producing cyanobacteria strains. With regard to that, a 
so far unknown member of the aeruginosin family, aeruginosin 828A, has been 
isolated from the Plankthothrix rubescens strain 91/1. In order to elucidate its 
structure, we obtained it in a pure form. HRMS experiments showed the putative 
molecular ions of m/z = 851.3019 [M+Na]+ and m/z = 853.3003 [M+Na]+, which 
correspond to a molecular formula of C36H5335ClN6O12SNa+ or C36H5337ClN6O12SNa+ 
respectively. The 749-fragment indicated the presence of a sulphate group. The 
characteristic isotopic pattern showed that the molecule was chlorinated (Figure 4.2).  
 
 
 
Figure 4.2. ESI mass spectrum of aeruginosin 828A (4.1) 
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Acid hydrolysis tests with aeruginosin 828A from Plankthothrix rubescens strain 91/1 
showed that it contains a derivatized leucyl residue and no arginine. To investigate 
the C-H-network of the unknown toxin, a series of NMR experiments were carried 
out. The 1H–NMR spectrum of aeruginosin 828A (4.1) revealed two sets of 
characteristic resonances for a peptide structure (amide protons in the range of 7.0 – 
8.0 ppm and "-protons in the range 4.0 – 5.0 ppm) (Spectrum 10). The constitution 
of each peptide-component was assigned using COSY, HSQC, HMBC and NOESY 
experiments. The measured chemical shifts are reported in Table 4.1. 2D-NMR 
experiments and comparison with the literature data led to the identification of the 
following building blocks: phenyllactic acid (Pla); chloroleucine (Cleu); a 2-carboxy-6-
(4’-sulfo-xylosyl)-octahydroindole moiety (Choi) and a 3-aminoethyl-1-N-amidino-#3-
pyrroline moiety (Aeap). All this classified the compound as a member of the 
aeruginosin family (Figure 4.3).  
 
 
 
 
 
 
 
 
 
Figure 4.3. NMR assignments of aeruginosin 828A (4.1) 
 
The position of the chlorine atom in Cleu was determined based on the 
characteristic chemical shift of the corresponding C$ atom of the Leu moiety 
(%c = 68.6 ppm).[11]  The presence of a xylose residue was suggested by the low-field 
shifted carbon atoms (%c & 70 ppm), which indicated the presence of oxygen 
substituents.  
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Table 4.1. 1H and 13C chemical shifts of aeruginosin 828A in DMSO (700MHz, DMSO-d6, 298K) 
Unit     C/H no.  %H (J in Hz)                                %C          HMBCa                             NOE 
Xyl 1eq 4.94 d (3.8) 95.0 Xyl 2,3,5, Choi 6 Choi 6, Xyl 2,4',7,7' 
 2ax 3.28 m 71.8 Xyl 3,5 Xyl 1,4 
 3ax 3.57 ddd (2.6, 9.0, 9.1) 71.4 Xyl 2,4,5 Xyl 4,5ax, 3-OH  
 4ax 3.93 ddd (5.8, 9.1, 10.6) 74.7 Xyl 3,5 Xyl 1,2,5ax,5eq,3-OH 
 5ax 3.36 dd (10.6, 10.7) 59.3 Xyl 1,3,4 Xyl 4,5eq 
 5eq 3.67 dd (5.8, 10.7)  Xyl 1,3,4 Xyl 4,5ax 
 2-
OH 
4.41 (7.3) - Xyl 1,2 - 
 3-
OH 
4.96 (2.6) - Xyl 2,3,5 Xyl 3,4 
Choi 1 - 171.
1 
- - 
 2 4.18 dd (9.4, 8.2) 59.5 Choi 1,3 Aeap NH, Choi 3,3',3a,7 
 3 2.01 ddd (12.6, 7.3, 7.3) 30.5 Choi 3a,7a Choi 2,3a,3',4',6,7',7a 
 3' 1.81 ddd (12.6, 12.6, 9.7) - Choi 1,2,3a Choi 2,3,3a,4',5',7 
 3a 2.25 m 35.6 Choi 3,4,5,7,7a Choi 2,3',4',7 
 4 2.14 m 19.1 Choi 3,3a,5 Choi 3a,4',5,5' 
 4' 1.48 m - Choi 5,6,7a Choi 3a,4,5',6 
 5 1.49 m 24.4 Choi 6,7a Choi 6,Cleu 2 
 5' 1.54 m - - Choi 3a,4,5,6,7' 
 6 3.83 m 68.4 - Choi 5,5',7,7', Xyl 5ax 
 7 1.58 dd (11.9, 12.9) 28.4 Choi 7a Cleu 2, Choi 6,7' 
 7' 2.25 m - Choi 5,7a Choi 2,6,7',7a, Cleu 2 
 7a 4.32 ddd (11.9, 6.4, 6.4) 54.1 Choi 2,3,3a,7, Cleu 
1 
Choi 4,4',7,7', Cleu 2,5 
Pla 1 - 172.
5 
- - 
 2 4.18 (br) 71.5 - Pla 3, 3' 
 3 2.79 dd (14.0, 7.6) 39.7 Pla 1,2,4,5,9 Pla 2,3' 
 3' 2.96 dd (14.0, 3.7) - Pla 1,2,4,5,9 Pla 2,3 
 4 - 137.
9 
- - 
 5,9 7.23 m 129.
5 
Pla 3,5,7,9 Pla 3,3',7 
 6,8 7.26 m 127.
7 
Pla 4,6,8 Pla 5,7,9 
 7 7.18 m 125.
8 
Pla 5,9 - 
 2-
OH 
- - - - 
Cleu 1 - 167.
4 
- - 
 2 4.93 dd (10.7,8.7) 50.9 Cleu 1,3, Pla 1 Cleu 3,4,5, Choi 7a,7,7' 
 3 4.00 dd (10.7, 1.8) 68.6 Cleu 1,2,4,5,5' Cleu 2,4,5' 
 4 1.71 dsept. (6.6, 1.8) 27.3 Cleu 5,5' Cleu 2,3,5 
 5 0.87 3H, d (6.6) 15.3 Cleu 3,4,5' Cleu 2,3,4 Choi 7',7a  5' 0.86 3H, d (6.6) 20.6 Cleu 3,4,5 
 NH 7.68 d (8.7) - - Cleu 3 
Aeap 1 3.16 dddd (13.0, 6.5, 6.5, 
5.7) 
36.3 Aeap 2,3, Choi 1 Aeap 2,4,5,6,NH, Choi 2  1' 3.23 dddd (13.0, 6.5, 6.5, 
5.7) 
- Aeap 2,3, Choi 1 
 2 2.25 2H, m 28.1 Aeap 1,3,4,6  Aeap 1,1',4,5,6,NH 
 3 - 136.
1 
- - 
 4 5.61 t (1.6) 119.
0 
Aeap 2,3,5,6  Aeap 1,1',2,5,6,NH 
 5 4.07 2H, d (1.6) 53.6 Aeap 3,4 Aeap 1,1',2,4  6 4.07 2H, s 54.9 Aeap 3,4 
 NH 8.00 dd (5.7, 5.7) - Aeap 1, Choi 1 Aeap 1,1',2,4,5,6, Choi 
2,3,3'  8 - 154.
9 
- - 
aHMBC correlations are given from proton(s) stated to the indicated carbon atom 
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The position of the sulphate group was established by the typical chemical 
shift of Xyl C-4 (%c = 74.7 ppm)[12], as well as by the COSY correlations between H-2 
(%H = 3.28 ppm) and Xyl OH-2 (%H = 4.41 ppm), and Xyl H-3 (%H = 3.57 ppm) and Xyl 
OH-3 (%H = 4.96 ppm) (Figure 4.4). The relative configuration of the carbohydrate 
moiety was assigned by the NOESY spectrum and J-coupling constants (Figure 4.4).  
 
 
 
 
 
 
 
 
Figure 4.4. Key COSY and NOE correlations in aeruginosin 828A (4.1) 
The "-anomer of the sugar moiety was identified by its small coupling constant 
(J = 3.8 Hz), which results from the (+)-sc arrangement between Xyl H-1 to Xyl H-2 
(Figure 4.5).  
 
 
 
 
 
Figure 4.5. J coupling between Xyl H-1 to Xyl H-2 
 
The configuration of the Choi moiety was determined using the relevant NOE 
correlations between Choi H-3’ (%H = 1.81 ppm) and Choi H-4’ (%H = 1.48 ppm), as 
well as Choi H-4 (%H = 2.14 ppm) and Choi H-3a (%H = 2.25 ppm), Choi H-3 
(%H = 2.01, 1.81 ppm) to Choi H-3a (%H = 2.25 ppm) and, additionally, to Choi H-6 
(%H = 3.83 ppm) and Choi H-7’ (%H = 2.25 ppm) (Table 4.1). The configuration of the 
C-6 stereogenic center of Choi was assigned on the basis of the line width of its 
signal (total ~ 16 Hz), which implies that no trans-diaxial relationship of the Choi H-6 
to its coupling partners is present (Figure 4.6, A).  
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Figure 4.6. Possible configurations of Choi C-6 
A: no trans-diaxial relationship of H-6 
B: trans-diaxial relationship of H-6 
 
Due to the lack of commercially available, authentic standards for the Cleu and 
Choi residues, we did not perform hydrolysis and subsequent analysis on chiral 
stationary phases. Nevertheless, the syntheses of these entities are currently being 
carried out in our laboratory, which would allow us to confirm the hypothesized 
configuration. The observed NOE between Choi H-3a and Choi H-7a supports the 
relative cis-configuration, which is further substantiated by numerous literature 
examples of identical configurations (Figure 4.7).  
 
 
 
 
 
 
Figure 4.7. Cis-configuration of Choi 
 
The tentatively assigned relative configuration of aeruginosin 828A (4.1) is 
further corroborated by comparison with data reported for the structurally similar 
aeruginosin 205B (Table 4.2).  
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Table 4.2. 1H and 13C chemical shifts of aeruginosin 828A in DMSO (700MHz, DMSO-d6, 298K) in 
comparison to1H and 13C chemical shifts of aeruginosin 205B as described by Hanessian et al.[13]  
 
Aeruginosin 828A  Natural aeruginosin 205B 
Unit          C/H no.     %H            %C               %H          %C           
Xyl 1eq 4.94   95.0  4.93 95.2 
 2ax 3.28   71.8  3.28 72.1 
 3ax 3.57   71.4  3.58 71.7 
 4ax 3.93   74.7  3.93 74.9 
 5ax 3.36   59.3  3.37 59.6 
 5eq 3.67     3.67  
 2-OH 4.41   -    
 3-OH 4.96   -    
Choi 1 - 171.1    
 2 4.18  59.5  4.19 59.8 
 3 2.01  30.5  2.02 30.8 
 3' 1.81  -  1.84  
 3a 2.25  35.6  2.24 35.8 
 4 2.14  19.1  2.13 19.4 
 4' 1.48  -  1.48  
 5 1.49  -  1.54 24.7 
 5' 1.54  24.4  1.54  
 6 3.83  68.4  3.83 68.7 
 7 1.58  28.4  1.59 28.7 
 7' 2.25  -  2.23  
 7a 4.32  54.1  4.23 54.2 
Pla 1 - 172.5   172.4 
 2 4.18  71.5  4.19 71.9 
 3 2.79  39.7  2.78 40.0 
 3' 2.96  -  2.93  
 4 - 137.9  - 137.9 
 5,9 7.23  129.5  7.23 129.6 
 6,8 7.26  127.7  7.25 127.9 
 7 7.18  125.8  7.18 126.0 
 2-OH - -  - - 
Cleu 1 - 167.4  - 167.3 
 2 4.93   50.9  4.9 51.1 
 3 4.00  68.6  3.98 68.9 
 4 1.71  27.3  1.69 27.5 
 5 0.87  15.3  0.88 15.4 
 5' 0.86  20.6  0.85 20.8 
 NH 7.68  -  7.62  
Aeap 1 3.16  36.3    
 1' 3.23  -    
 2 2.25  28.1    
 3 - 136.1    
 4 5.61  119.0    
 5 4.07  53.6    
 6 4.07  54.9    
 NH 8.00  -    
 8 - 154.9    
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The difference between aeruginosin 828A and aeruginosin 205B is the 
presence of an agmatine moiety instead of the Aeap residue and shows almost 
identical 1H and 13C shifts (maximal shift 0.3 ppm in the 1H-NMR and 0.4 ppm in the 
13C-NMR spectra). An (R)-configuration for the C-2 of Pla and C-3 of Cleu building 
blocks, as well as the (S)-configuration for the C-2 of Cleu was tentatively assigned. 
We are aware that its final structure elucidation will require the use of total chemical 
synthesis. To validate such preliminary assignments, the synthesized aeruginosin 
828A with the known configuration will be used for direct comparison to the natural 
product. 
 
 
 
 
 
 
 
 
Figure 4.8. Key HMBC and NOE correlations in aeruginosin 828A (4.1) 
 
The assembly of the different fragments was established by HMBC and 
NOESY experiments (Figure 4.8). The linkage between central Choi and the Cleu 
was suggested by the HMBC correlation between Choi H-7" (%H = 4.32 ppm) and 
Cleu C-1 (%c = 167.4 ppm). In a similar fashion, the connection between the Choi and 
the Aeap residues was determined by the coupling between Aeap H-1 and H-1’ 
(%H = 3.16 ppm and 3.23 ppm) and Choi C-1 (%c = 171.1 ppm). The HMBC correlation 
from Cleu H-2 (%H = 4.93 ppm) to Pla C-1 (%c = 172.5 ppm) demonstrated the 
connection of these moieties. In addition, the connection of the Xylose unit with the 
Choi moiety was elucidated by the NOE correlation of the Xyl H-1 (%H = 4.94 ppm) to 
Choi H-6 (%H = 3.83 ppm) as well as an HMBC correlation. 
Interestingly, our cooperation partner described for aeruginosin 828A not only 
thrombin (IC50 = 21.8 nM) and trypsin (IC50 = 112 nM) inhibition ability, as it exhibits 
activity towards Thamnocephalus platyurus (LC50 = 22.4 'M). This is the first time 
such activity was observed within this compound class. Additional toxicity tests were 
carried out with aeruginosins containing only sulphate or neither sulphate, nor 
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chlorine moiety. These tests showed, that aeruginosins shows toxicity against 
aquatic organisms only if a sulphate group and a chlorine are present. Intriguingly, 
this toxic sulphate and chlorine-containing compound class was only found in 
microcystin-deficient strains. These interesting findings indicate, that these molecules 
can be a substitute for microcystins.  
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4.3 Conclusion 
 
The structure of aeruginosin 828A isolated from P. rubescens strain 91/1 was 
elucidated. The presence of phenyllactic acid (Pla), chloroleucine (Cleu), 
2-carboxy-6-(4’-sulfo-xylosyl)-octahydroindole residue (Choi) and a 3-aminoethyl-
1-N-amidino-#3-pyrroline moiety (Aeap) was confirmed by 2D-NMR experiments. 
These supports that the compound as a member of the aeruginosin family. It exhibits 
trypsin and thrombin inhibitory activity in low nanomolar concentrations and shows 
toxicity against Thamnocephalus platyurus comparable to that of microcystins. This 
compound was found only in microcystin-deficient cyanobacterial strains, which 
makes us believe it has a similar function to compensate the lack of microcystins. 
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4.4 Methods 
 
1H-NMR spectra were recorded on a Bruker Avance III Ultrashield 600MHz with a 
5mm BBFO+ plus SP probe or a Bruker Avance III Ascend 700MHz with a 5mm TCI 
(H-C/N-D) cryo probe spectrometers at room temperature. Chemical shifts (%-values) 
are reported in ppm, spectra were calibrated related to solvent`s residual proton 
chemical shift (DMSO, % = 2.50). Multiplicity is reported as follows: s = singlet, 
bs = broad singlet, d = doublet, dd = doublet of doublet, t = triplet, m = multiplet. The 
coupling constant J is specified in Hz. HRMS spectra were obtained on a Bruker 
maXis 4G with ESI in positive mode.  
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5.1 Introduction 
 
Cyanopeptolins (CP) are an abundant, but not very well studied group of cyclic 
depsipeptides deriving from cyanobacteria. They are mainly isolated from the genus 
Anabaena, Microcystis and Planktothrix, as not all strains from the same family are 
able to produce these toxins.[1] There are also cyanobacterial strains, which are able 
to synthesize more than one variant of this compound class. This is the case for 
Microcystis HUB08B03, where 13 different cyanopeptolins variants were found within 
the same strain.[2] Usually other toxic molecules, mainly microcystins, are also 
produced along with these toxins.[3] As microcystins, cyanopeptolins are synthesized 
via the non-ribosomal pathway and show, due to this, a great structural variety.[4] 
Their core structure contains seven amino acids, six of them constitute a cyclic 
system.[4] Positions R1 and R2 show high structural variability of the proteinogenic 
amino acids (e.g. Arg, Lys, Phe). In contrast, position R3 is restricted to Ile or Val 
(Figure 5.1).[4]  
 
 
 
 
 
 
 
 
Figure 5.1. General structure of cyanopeptolin 
 
The main structural diversity is observed in the side-chain, where different 
amino acids or non-amino acid constituents (e.g. fatty acid) can be incorporated.[5] 
The common structural elements that cyanopeptolin variants share are the unusual 
amino acid 3-amino-6-hydroxy-2-piperidone (Ahp) and an ester connectivity between 
the !-OH group of Thr and the C-terminal amino acid.[3,4] Concerning biological 
activity, cyanopeptolins are protease-inhibitors, active on serine or threonine-
proteases, such as chymotrypsin or trypsin.[6,7] One member of this compound class 
is cyanopeptolin 1020 (CP1020), which has been isolated in our group in 2010 from a 
Microcystis strain (Figure 5.2).[8]  
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Figure 5.2. Structure of cyanopeptolin 1020 
 
This highly potent toxin inhibits trypsin with an inhibitory concentration in the 
picomolar range, and human kallikrein and factor Xia with an inhibitory concentration 
in the nanomolar range.[8] Furthermore, it shows toxic activity against the freshwater 
crustacean Thamnocephalus playturus with an LC50 value of 8.8 "M, which is in the 
same range as the microcystins. Recent studies on global transcriptome analysis in 
Danio rerio embryos showed that CP1020 acts on DNA-damage recognition and 
repair, circadian rhythm, and response behaviour to light. [9] These findings showed, 
that CP1020 causes DNA-damage and has neurotoxic properties.[9] This peptide 
consists of eight residues: Glu, Thr, Arg, Ahp, Phe, N-Me-Tyr, Val, and hexanoic 
acid, as the Glu residue is not involved in enzyme binding as showed by a model 
structure.[8] As CPs and particularly CP1020 have not been investigated in detail, the 
goal of this study was to develop a labelling procedure for the carboxylic acid moiety 
of CP1020.  
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5.2 Results and discussion 
5.2.1 Synthesis of modified CP1020 
 
Cyanopeptolin1020, isolated from Microcystis aeruginosa UV-006, was used for the 
reactions. The limited amount of the toxin presented a major challenge to its 
modification. Also the unknown extinction coefficient of the toxin, which is especially 
required for yield determination, posed a problem. Our strategy was to find an 
efficient protocol for labelling the Glu function via amide bond formation. Another 
obstacle was the sensitivity of the toxin as for example, the ester function on the 
threonine-residue easily eliminates to form a double bond and the free carboxylic 
acid (Figure 5.3).  
 
 
 
 
 
 
 
Figure 5.3. Undesired degradation product of CP1020 
 
 A careful screen identified DMSO as the best solvent for CP1020. The toxin, 
however, was not stable in that solvent when stored at -20 °C, which necessitated to 
work with small freshly prepared aliquots (50 "g). We first treated CP1020 with 
10 % pyridine in DMF, DCC (1.1 eq.), 1-hydroxybenzotriazole (1.5 eq.) and 
5-((2-aminoethyl)amino)naphthalene-1-sulfonic acid (1.5 eq.) for eight hours, 
however, no product formation was observed. The use of a catalytic amount of 
DMAP did not improve the reactivity. Then, another standard peptide coupling 
procedure was attempted: 5-((2-aminoethyl)amino)naphthalene-1-sulfonic acid 
(1.5 eq.), NEt3 and TBTU (1.2 eq.). However, these conditions gave a complex 
reaction mixture. These results could be due to the instability of the fluorophore. For 
this reason, Alexa 488 cadaverine sodium salt was used, known for its higher 
stability. A first attempt using Alexa 488 cadaverine sodium salt (1.1 eq.), NEt3 (2 eq.) 
and TBTU (1.1 eq.) was undertaken. To follow this reaction, a sample was taken 
after one hour and analysed by LC-MS. It was observed that the starting material 
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was fully converted, but no peak with the desired product mass could be detected. 
The change of the coupling reagent to HATU (1.1 eq.) did not influence the reactivity. 
Also with pyridine (2 eq.), HATU (1.1 eq.) and Alexa 488 cadaverine sodium salt 
(1.1 eq.) no desired product mass could be detected. One problem was supposed to 
be the size of the fluorophore that might be unable to access the Glu position in 
CP1020. Furthermore, an intermolecular reaction between the arginine and the 
activated carboxylic acid is possible. To exclude these hypotheses, a small and 
highly nucleophilic amine was chosen. In this context, benzylamine, HATU and 
pyridine were used in excess. After one hour, no starting material could be observed, 
neither desired product formation. A change to NEt3 did not lead to better results. 
These observations suggested, that CP1020 might be sensitive towards NEt3. 
CP1020 treated with excess of NEt3 showed absence of the starting material, but 
rather the presence of another species of m/z 467 which Portmann previously 
identified this fragment by MS-MS studies as Hex-Glu-didehydrobutyrate-Arg.[10]  This 
fragment is formed by an elimination reaction at the threonine function and cleavage 
of the peptide bond at Arg. We believe that the use of a base together with CP1020 
enhances this undesired side-reaction. In this context, the use of a bulkier base was 
expected to overcome the problem. Two test reactions with Hünig’s base 
(N,N-diisopropylethylamine) or DBU identified the former as a good candidate for the 
coupling reaction. Attempts with Hünig’s base, benzylamine and HATU or TBTU did 
not yield the desired product. However, a combination of Hünig’s base, benzylamine 
and EDC resulted in formation of a species with the desired mass. A 
coumarin-derivative of the toxin was also synthesized using the same protocol 
(Figure 5.4).  
 
 
 
 
 
 
 
 
 Figure 5.4. Derivatization of CP1020 
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Unfortunately, the obtained products were rather unstable, as decomposition was 
observed directly after purification. The coumarin derivative 5.2 was particularly 
unstable and its identity was only supported by MS. 
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5.5 Conclusion 
 
Derivatization of CP1020 by a variety of conditions proved to be difficult and 
inefficient, mainly due to the instability of the toxin. Partial success was achieved with 
Hünig’s base and EDC. The resulting species, however, were quite labile and no 
further biological tests could be performed. A more detailed screening of coupling 
conditions, tag moieties, and purification strategies is required for an increased 
stability of the products.  
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5.4 Methods 
5.4.1 General !
All chemicals were purchased from Sigma-Aldrich Co., were of analytical grade and 
freshly distilled before use. HPLC purifications of the functionalized CP1020 were 
performed on a Dionex P-680 HPLC System with a Phenomenex Gemini C18 5µ 
(250 mm x 4.6 mm) column or a Phenomenex Gemini C18 5µ (150 mm x 4.6 mm) 
column using a linear gradient: 5 % to 100 % CH3CN in 0.1 % Formic acid/H2O over 
40 minutes at a flow rate of 1 mL/min. As ionization method electrospray ionization 
was used. HRMS spectra were obtained on a Bruker maXis 4G with ESI in positive 
mode. MS-MS experiments were obtained on a Bruker Esquire 3000 with ESI in 
positive mode. 
5.4.2 Cell culturing, extraction and isolation 
 
Microcystis aeruginosa UV-006 was cultivated in 500mL Falcon tubes in 200 mL 
mineral medium at 25 °C with 12 h light and night cycle.[11] The resulting biomass was 
harvested every three months with a 6K15 centrifuge (Sigma), freezed and stored 
at -20 °C. To obtain pure CP1020 without methylated product, the cyanobacteria 
were suspended in 20 mL of 60% acetonitrile per 1 g biomass and sonicated for 
10 min (Branson 2510). The resulting homogenous mixture was centrifuged for 
15 min at 25000 x g and the supernatants were combined and evaporated in a 
rotarory evaporator (Büchi, Switzerland). The residue was dissolved in 60 % 
acetonitrile and prepurified on a C18 SPE cartridge (10 g, Supelco). The crude 
mixture was eluted with 80 % acetonitrile (500 mg biomass afforded 15 mg crude 
extract), concentrated and applied on a Dionex P-680 HPLC System with a 
Phenomenex Gemini-NX C18 5 µ (75 mm x 21.2 mm) column using a linear gradient: 
5 % to 100 % CH3CN in 0.1 % Formic acid/H2O over 40 minutes at a flow rate of 
5 mL/min for further purification. For removal of the formic acid a final purification 
step was performed on a C18 SPE cartridge (500 mg, Supelco) starting with a first 
washing step with water to remove the acid and a final elution step with 80 % 
acetonitrile. After removal of all volatiles and lyophilisation pure CP1020 (900 "g from 
15 mg crude extract) was afforded as a white solid. HPLC: tR = 14.4 min; MS (ESI): 
m/z = 1021.5 [M+H]+ 
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5.4.3 Synthesis of modified CP1020 
 
 
 
 
 
 
 
 
CP1020-(Bn), (5.1): Compound 5.1 was synthesized starting from CP1020 dissolved 
in DMSO (50 "g, 0.05 µmol). Hünig’s base, EDC and benzylamine were added in 
excess. The mixture was stirred for 1.5 h at room temperature. Purification by HPLC 
afforded 5.1 as a white solid. (Due to the missing extinction coefficient no yield can 
be reported) HPLC: tR = 17.9 min; HRMS-ESI: calcd. for C57H80N11O12+ [M+H]+: 
1110.5982; found: 1110.5982. 
 
 
 
 
 
 
 
 
 
CP1020-(coumarin), (5.2): Compound 5.2 was synthesized starting from CP1020 
dissolved in DMSO (50 "g, 0.05 µmol). Hünig’s base, EDC and 7-amino-4-
methylcoumarin were added in excess. The mixture was stirred for 1.5 h at room 
temperature. Purification by HPLC afforded 5.2 as a white solid. (Due to the missing 
extinction coefficient no yield can be reported) HPLC: tR = 11.8 min; MS-ESI: calcd. 
for C60H81N11O14 2+ [M+H+H]2+:589.2; found: 589.2. (Due to the high instability of the 
compound no HRMS could be recorded) 
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6. Conclusion 
 
The present work addresses important questions concerning the structure, 
modification and biological activity of a group of secondary metabolites, produced by 
cyanobacteria. The detailed investigation of the chemistry and toxicity of MC-LR and 
CP1020 (isolated from Microcystis aeruginosa UV-006) and the structure elucidation 
of an unknown toxin isolated from Plankthothrix rubescens are key elements of this 
work.  
 
As only limited amounts of microcystin-LR were available for testing, a method for 
efficient labelling of the arginine-containing peptides was developed. Various 
peptides were prepared and applied to different syntheses strategies. An established 
method was finally tested with several substrates in order to detect limitations. Future 
work will concentrate on elaborating the method for peptides containing as well 
cysteine-residues. 
 
The new method, initially tested on model peptides, was applied to modification of 
microcystin-LR. Fluorescent, biotin and diazirine derivatives were synthesized and 
tested to assess whether the biological activity of the parent compound had been 
retained. Enzyme phosphatase 2A inhibition assays, acute toxicity assays and cell 
viability assays showed maintained activity of the derivatives. Further tests in Danio 
rerio and Daphnia magna will be performed with fluorescent microcystin-LR by our 
cooperation partner (Susanne Faltermann, University of Applied Sciences and Arts 
Northwestern Switzerland) to answer open questions regarding uptake, distribution, 
accumulation and excretion of microcystin-LR. 
 
The structure of a newly isolated toxin [aeruginosin 828A] from the Plankthothrix 
rubescens strain 91/1 was elucidated using NMR studies and MS-characterization. 
This compound is a member of the aeruginosin family, it contains phenyllactic acid 
(Pla), chloroleucine (Cleu), a 2-carboxy-6-(4’-sulfo-xylosyl)-octahydroindole moiety 
(Choi) and a 3-aminoethyl-1-N-amidino-!3-pyrroline moiety (Aeap). Toxicity towards 
the aquatic organism, Thamnocephalus platyurus, was proven in a biological study 
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for the first time. In the future, further in vivo studies in Daphnia magna will be 
conducted to investigate the mode of action.  
 
A new approach towards the modification of the toxin cyanopeptolin 1020 was 
achieved and a benzylamine and a fluorescent derivative were synthesized. Although 
the target modified species were detected by MS-techniques and isolated, further 
studies were not possible, due to the instability of the modification products. 
Additional tests in that direction would bring us one step closer to complete 
understanding of the function of the fascinating compound class. In the future, a 
more detailed screening of coupling conditions, tag moieties, and purification 
strategies will be performed. 
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7.1 Chromatograms 
 
Chromatogram 1. HPLC trace of Bz-Arg(Dansyl)-OMe (2.1) 
Chromatogram 2. HPLC trace of Bz-Arg(N-succinimid)-OEt (2.2) 
Chromatogram 3. HPLC trace of Boc-Arg(N-succinimid)-OH (2.3) 
Chromatogram 4. HPLC trace of N-Ac-Arg(Alexa488)-OH (2.4) 
Chromatogram 5. HPLC trace of N-Ac-Arg(6-FAM)-OH (2.5) 
Chromatogram 6. HPLC trace of N-Ac-Arg(coumarin)-OH (2.6) 
Chromatogram 7. HPLC trace of N-Ac-Gly-Val-Phe-Arg-Gly-OH (2.7) 
Chromatogram 8. HPLC trace of N-Ac-Gly-Val-Glu-Phe-Arg-Gly-OH (2.8) 
Chromatogram 9. HPLC trace of N-Ac-Gly-Lys-Phe-Arg-Gly-OH (2.9) 
Chromatogram 10. HPLC trace of N-Ac-Gly-Phe-Arg-Arg-Gly-OH (2.10) 
Chromatogram 11. HPLC trace of N-Ac-Gly-Phe-Val-Arg-Gly-Val-Gly-OH (2.11) 
Chromatogram 12. HPLC trace of N-Ac-Gly-Val-Arg-Phe-Ser-Gly-OH (2.12) 
Chromatogram 13. HPLC trace of N-Ac-Gly-Val-Cys-Arg-Phe-Gly-OH (2.13) 
Chromatogram 14. HPLC trace of N-Ac-Gly-Phe-His-Ala-Arg-Gly-OH (2.14) 
Chromatogram 15. HPLC trace of N-Ac-Gly-Val-Dha-Arg-Phe-Gly-OH (2.15) 
Chromatogram 16. HPLC trace of N-Ac-Gly-Val-Phe-Arg(6-FAM)-Gly-OH (2.16) 
Chromatogram 17. HPLC trace of N-Ac-Gly-Val-Glu-Phe-Arg(6-FAM)-Gly-OH (2.17) 
Chromatogram 18. HPLC trace of N-Ac-Gly-Val-Arg(6-FAM)-Phe-Ser-Gly-OH (2.18) 
Chromatogram 19. HPLC trace of N-Ac-Gly-Phe-His-Ala-Arg(6-FAM)-Gly-OH (2.19) 
Chromatogram 20. HPLC trace of N-Ac-Gly-Phe-Arg(6-FAM)-Arg(6-FAM)-Gly-OH (2.20) 
Chromatogram 21. HPLC trace of N-Ac-Gly-Phe-Val-Arg(6-FAM)-Gly-Val-Gly-OH (2.21) 
Chromatogram 22. HPLC trace of N-Ac-Gly-Val-Dha-Arg(6-FAM)-Phe-Gly-OH (2.22) 
Chromatogram 23. HPLC trace of N-Ac-Gly-Val-Cys(6-FAM)-Arg-Phe-Gly-OH (2.23) 
Chromatogram 24. HPLC trace of N-Ac-Gly-Lys(6-FAM)-Phe-Arg-Gly-OH (2.24) 
Chromatogram 25. HPLC trace of N-Ac-Gly-Phe-Val-Arg(Biotin)-Gly-Val-Gly-OH (2.25) 
Chromatogram 26. HPLC trace of N-Ac-Gly-Val-Glu-Phe-Arg(Biotin)-Gly-OH (2.26) 
Chromatogram 27. HPLC trace of N-Ac-Gly-Phe-Val-Arg(DA)-Gly-Val-Gly-OH (2.27) 
Chromatogram 28. HPLC trace of N-Ac-Gly-Val-Glu-Phe-Arg(DA)-Gly-OH (2.28) 
Chromatogram 29. HPLC trace of Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg(6-FAM)-Pro-NHEt (2.30) 
Chromatogram 30. HPLC trace of N-Ac-Gly-Lys(Boc)-Phe-Arg-Gly-OH (2.31) 
Chromatogram 31. HPLC trace of N-Ac-Gly-Lys(Boc)-Phe-Arg(6-FAM)-Gly-OH (2.32) 
Chromatogram 32. HPLC trace of N-Ac-Gly-Lys-Phe-Arg(6-FAM)-Gly-OH (2.33) 
Chromatogram 33. HPLC trace of MC-LR  
Chromatogram 34. HPLC trace of MC-LR-(6-FAM) (3.1) 
Chromatogram 35. HPLC trace of MC-LR-(Alexa-430) (3.2) 
Chromatogram 36. HPLC trace of MC-LR-(Alexa-488) (3.3) 
Chromatogram 37. HPLC trace of MC-LR-(Texas-Red) (3.4) 
Chromatogram 38. HPLC trace of MC-LR-(Biotin) (3.5) 
Chromatogram 39. HPLC trace of MC-LR-(DA) (3.6) 
!!
7 Appendix 
!
! !
170 
Chromatogram 40. HPLC trace of CP1020 
Chromatogram 41. HPLC trace of CP1020(Benzylamin) (5.1) 
Chromatogram 42. HPLC trace of CP1020(Coumarin) (5.2) ! !
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Chromatogram 1. HPLC trace of Bz-Arg(Dansyl)-OMe (2.1) 
 
 
Chromatogram 2. HPLC trace of Bz-Arg(N-succinimid)-OEt (2.2) 
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Chromatogram 3. HPLC trace of Boc-Arg(N-succinimid)-OH (2.3) 
 
 
Chromatogram 4. HPLC trace of N-Ac-Arg(Alexa488)-OH (2.4) 
 
Operator:Dionex  Timebase:MSQ_Summit   Sequence:MC-LR Page 1-1
6.2.2014  5:17 PM
Verena-pdf/Overlay UV/MS Spectra Print
Chromeleon (c) Dionex 1996-2006
Version 6.80 DU11c Build 3199 (190670)
Overlay of Samples and Spectra from Integration View
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0
-100
0
100
200
300
400
500
600
mAU
min
WVL:225 nm
Operator:Dionex  Timebase:MSQ_Summit   Sequence:25.07.12 Page 1-1
3.2.2014  10:13 AM
Verena-pdf/Overlay UV/MS Spectra Print
Chromeleon (c) Dionex 1996-2006
Version 6.80 DU11c Build 3199 (190670)
Overlay of Samples and Spectra from Integration View
0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.4
-5.0
0.0
5.0
10.0
15.0
20.0
25.0
30.0
mAU
min
WVL:488 nm
H
N
O
OH
NH
NHHN
H
OO
O
O
O
O
H2N
NH2
O3S
O3S
HN
H
N
O
OH
O
H
2 Li
OH
O
!!
7 Appendix 
!
! !
173 
 
Chromatogram 5. HPLC trace of N-Ac-Arg(6-FAM)-OH (2.5) 
 
 
Chromatogram 6. HPLC trace of N-Ac-Arg(coumarin)-OH (2.6) 
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Chromatogram 7. HPLC trace of N-Ac-Gly-Val-Phe-Arg-Gly-OH (2.7) 
 
 
Chromatogram 8. HPLC trace of N-Ac-Gly-Val-Glu-Phe-Arg-Gly-OH (2.8) 
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Chromatogram 9. HPLC trace of N-Ac-Gly-Lys-Phe-Arg-Gly-OH (2.9) 
 
 
Chromatogram 10. HPLC trace of N-Ac-Gly-Phe-Arg-Arg-Gly-OH (2.10) 
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Chromatogram 11. HPLC trace of N-Ac-Gly-Phe-Val-Arg-Gly-Val-Gly-OH (2.11) 
 
 
Chromatogram 12. HPLC trace of N-Ac-Gly-Val-Arg-Phe-Ser-Gly-OH (2.12) 
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Chromatogram 13. HPLC trace of N-Ac-Gly-Val-Cys-Arg-Phe-Gly-OH (2.13) 
 
 
Chromatogram 14. HPLC trace of N-Ac-Gly-Phe-His-Ala-Arg-Gly-OH (2.14) 
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Chromatogram 15. HPLC trace of N-Ac-Gly-Val-Dha-Arg-Phe-Gly-OH (2.15) 
 
 
Chromatogram 16. HPLC trace of N-Ac-Gly-Val-Phe-Arg(6-FAM)-Gly-OH (2.16) 
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Chromatogram 17. HPLC trace of N-Ac-Gly-Val-Glu-Phe-Arg(6-FAM)-Gly-OH (2.17) 
 
 
Chromatogram 18. HPLC trace of N-Ac-Gly-Val-Arg(6-FAM)-Phe-Ser-Gly-OH (2.18) 
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Chromatogram 19. HPLC trace of N-Ac-Gly-Phe-His-Ala-Arg(6-FAM)-Gly-OH (2.19) 
 
 
Chromatogram 20. HPLC trace of N-Ac-Gly-Phe-Arg(6-FAM)-Arg(6-FAM)-Gly-OH (2.20) 
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Chromatogram 21. HPLC trace of N-Ac-Gly-Phe-Val-Arg(6-FAM)-Gly-Val-Gly-OH (2.21) 
 
 
Chromatogram 22. HPLC trace of N-Ac-Gly-Val-Dha-Arg(6-FAM)-Phe-Gly-OH (2.22) 
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Chromatogram 23. HPLC trace of N-Ac-Gly-Val-Cys(6-FAM)-Arg-Phe-Gly-OH (2.23) 
 
 
Chromatogram 24. HPLC trace of N-Ac-Gly-Lys(6-FAM)-Phe-Arg-Gly-OH (2.24) 
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Chromatogram 25. HPLC trace of N-Ac-Gly-Phe-Val-Arg(Biotin)-Gly-Val-Gly-OH (2.25) 
 
 
Chromatogram 26. HPLC trace of N-Ac-Gly-Val-Glu-Phe-Arg(Biotin)-Gly-OH (2.26) 
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Chromatogram 27. HPLC trace of N-Ac-Gly-Phe-Val-Arg(DA)-Gly-Val-Gly-OH (2.27) 
 
 
Chromatogram 28. HPLC trace of N-Ac-Gly-Val-Glu-Phe-Arg(DA)-Gly-OH (2.28) 
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Chromatogram 29. HPLC trace of Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg(6-FAM)-Pro-NHEt 
(2.30) 
 
 
Chromatogram 30. HPLC trace of N-Ac-Gly-Lys(Boc)-Phe-Arg-Gly-OH (2.31) 
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Chromatogram 31. HPLC trace of N-Ac-Gly-Lys(Boc)-Phe-Arg(6-FAM)-Gly-OH (2.32) 
 
 
Chromatogram 32. HPLC trace of N-Ac-Gly-Lys-Phe-Arg(6-FAM)-Gly-OH (2.33) 
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Chromatogram 33. HPLC trace of MC-LR  
 
 
 
Chromatogram 34. HPLC trace of MC-LR-(6-FAM) (3.1) 
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Chromatogram 35. HPLC trace of MC-LR-(Alexa-430) (3.2) 
 
 
Chromatogram 36. HPLC trace of MC-LR-(Alexa-488) (3.3) 
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Chromatogram 37. HPLC trace of MC-LR-(Texas-Red) (3.4) 
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Chromatogram 38. HPLC trace of MC-LR-(Biotin) (3.5) 
 
 
Chromatogram 39. HPLC trace of MC-LR-(DA) (3.6) 
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!
Chromatogram 40. HPLC trace of CP1020 !
!
Chromatogram 41. HPLC trace of CP1020(Benzylamin) (5.1)! 
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Chromatogram 42. HPLC trace of CP1020(Coumarin) (5.2) 
 !
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3.4.2014  10:47 AM
Verena-pdf/Overlay UV/MS Spectra Print
Chromeleon (c) Dionex 1996-2006
Version 6.80 DU11c Build 3199 (190670)
Overlay of Samples and Spectra from Integration View
6.1 7.5 8.8 10.0 11.3 12.5 13.8 15.0 16.3 18.0
-15
50
100
150
200
282
mAU
min
WVL:191 nm
Error during access of raw data file "C:\Chromel\data\Verena\MC-LR2014\MC-LR.SEQ\XRAW.CHL\28041.raw":
The MS raw file does not exist!
Peak #1 100% at 1.47 min
-20
25
50
75
120
190 250 300 350 400 450 500 550 600 650
%
nm
200.4
227.7
398.7
 50% at 0.76 min:  142.64
 -50% at 1.52 min:  999.20
NH
N
H
O
N
H
N
O
N
O
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OH
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H
H
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7.2 NMR-Spectra 
 
NMR spectrum 1. 1H NMR spectrum of N-Ac-Gly-Val-Phe-Arg-Gly-OH (2.7) in DMSO-d6 (400MHz) 
NMR spectrum 2. 1H NMR spectrum of N-Ac-Gly-Val-Glu-Phe-Arg-Gly-OH (2.8) in DMSO-d6 
(400MHz) 
NMR spectrum 3. 1H NMR spectrum of N-Ac-Gly-Lys-Phe-Arg-Gly-OH (2.9) in DMSO-d6 (400MHz)!!
NMR spectrum 4. 1H NMR spectrum of N-Ac-Gly-Phe-Arg-Arg-Gly-OH (2.10) in DMSO-d6 (400MHz) 
NMR spectrum 5. 1H NMR spectrum of N-Ac-Gly-Phe-Val-Arg-Gly-Val-Gly-OH (2.11) in DMSO-d6 
(400MHz) 
NMR spectrum 6. 1H NMR spectrum of N-Ac-Gly-Val-Arg-Phe-Ser-Gly-OH (2.12) in DMSO-d6 
(400MHz) 
NMR spectrum 7. 1H NMR spectrum of N-Ac-Gly-Val-Cys-Arg-Phe-Gly-OH (2.13) in DMSO-d6 
(400MHz) 
NMR spectrum 8. 1H NMR spectrum of N-Ac-Gly-Phe-His-Ala-Arg-Gly-OH (2.14) in DMSO-d6 
(400MHz) 
NMR spectrum 9. 1H NMR spectrum of N-Ac-Gly-Val-Dha-Arg-Phe-Gly-OH (2.15) in DMSO-d6 
(400MHz) 
NMR spectrum 10. 1H NMR spectrum of MC-LR-(6-FAM) (3.1) in DMSO-d6 (700MHz)  
NMR spectrum 11. 1H NMR spectrum of aeruginosin 828A in DMSO-d6 (700MHz)  
NMR spectrum 12. HMBC NMR spectrum of aeruginosin 828A in DMSO-d6 (700MHz) 
NRM spectrum 13. NOESY NMR spectrum of aeruginosin 828A in DMSO-d6 (700MHz) 
NMR spectrum 14. COSY NMR spectrum of aeruginosin 828A in DMSO-d6 (700MHz) 
NMR spectrum 15. HMQC NMR spectrum of aeruginosin 828A in DMSO-d6 (700MHz) 
 
!!
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NMR spectrum 1. 1H NMR spectrum of N-Ac-Gly-Val-Phe-Arg-Gly-OH (2.7) in DMSO-d6 (400MHz) 
 
 
NMR spectrum 2. 1H NMR spectrum of N-Ac-Gly-Val-Glu-Phe-Arg-Gly-OH (2.8) in DMSO-d6 
(400MHz) 
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NMR spectrum 3. 1H NMR spectrum of N-Ac-Gly-Lys-Phe-Arg-Gly-OH (2.9) in DMSO-d6 (400MHz)! 
 
 
NMR spectrum 4. 1H NMR spectrum of N-Ac-Gly-Phe-Arg-Arg-Gly-OH (2.10) in DMSO-d6 (400MHz) 
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NMR spectrum 5. 1H NMR spectrum of N-Ac-Gly-Phe-Val-Arg-Gly-Val-Gly-OH (2.11) in DMSO-d6 
(400MHz) 
 
 
NMR spectrum 6. 1H NMR spectrum of N-Ac-Gly-Val-Arg-Phe-Ser-Gly-OH (2.12) in DMSO-d6 
(400MHz) 
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NMR spectrum 7. 1H NMR spectrum of N-Ac-Gly-Val-Cys-Arg-Phe-Gly-OH (2.13) in DMSO-d6 
(400MHz) 
 
 
NMR spectrum 8. 1H NMR spectrum of N-Ac-Gly-Phe-His-Ala-Arg-Gly-OH (2.14) in DMSO-d6 
(400MHz) 
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NMR spectrum 9. 1H NMR spectrum of N-Ac-Gly-Val-Dha-Arg-Phe-Gly-OH (2.15) in DMSO-d6 
(400MHz) 
 
 
NMR spectrum 10. 1H NMR spectrum of MC-LR-(6-FAM) (3.1) in DMSO-d6 (700MHz)  
!
NMR spectrum 11. 1H NMR spectrum of aeruginosin 828A in DMSO-d6 (700MHz)  
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NMR spectrum 12. HMBC NMR spectrum of aeruginosin 828A in DMSO-d6 (700MHz) 
 
NRM spectrum 13. NOESY NMR spectrum of aeruginosin 828A in DMSO-d6 (700MHz) 
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NMR spectrum 14. COSY NMR spectrum of aeruginosin 828A in DMSO-d6 (700MHz) 
 
NMR spectrum 15. HMQC NMR spectrum of aeruginosin 828A in DMSO-d6 (700MHz) 
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7.3 HRMS/MS-Spectra 
 
HRMS spectrum 1. Positive ionisation of Bz-Arg(Dansyl)-OMe (2.1) 
HRMS spectrum 2. Positive ionisation of Bz-Arg(N-succinimid)-OEt (2.2)!
HRMS spectrum 3. Positive ionisation of Boc-Arg(N-succinimid)-OH (2.3)!
HRMS spectrum 4. Negative ionisation of N-Ac-Arg(Alexa488)-OH (2.4)!
HRMS spectrum 5. Positive ionisation of N-Ac-Arg(6-FAM)-OH (2.5)!
HRMS spectrum 6. Positive ionisation of N-Ac-Arg(coumarin)-OH (2.6)!
HRMS spectrum 7. Positive ionisation of N-Ac-Gly-Val-Phe-Arg-Gly-OH (2.7) 
HRMS spectrum 8. Positive ionisation of N-Ac-Gly-Val-Glu-Phe-Arg-Gly-OH (2.8) 
HRMS spectrum 9. Positive ionisation of N-Ac-Gly-Lys-Phe-Arg-Gly-OH (2.9) 
HRMS spectrum 10. Positive ionisation of N-Ac-Gly-Phe-Arg-Arg-Gly-OH (2.10) 
HRMS spectrum 11. Positive ionisation of N-Ac-Gly-Phe-Val-Arg-Gly-Val-Gly-OH (2.11) 
HRMS spectrum 12. Positive ionisation of N-Ac-Gly-Val-Arg-Phe-Ser-Gly-OH (2.12) 
HRMS spectrum 13. Positive ionisation of N-Ac-Gly-Val-Cys-Arg-Phe-Gly-OH (2.13) 
HRMS spectrum 14. Positive ionisation of N-Ac-Gly-Phe-His-Ala-Arg-Gly-OH (2.14) 
HRMS spectrum 15. Positive ionisation of N-Ac-Gly-Val-Dha-Arg-Phe-Gly-OH (2.15) 
HRMS spectrum 16. Positive ionisation of N-Ac-Gly-Val-Phe-Arg(6-FAM)-Gly-OH (2.16) 
HRMS spectrum 17. Negative ionisation of N-Ac-Gly-Val-Glu-Phe-Arg(6-FAM)-Gly-OH (2.17) 
HRMS spectrum 18. Negative ionisation of N-Ac-Gly-Val-Arg(6-FAM)-Phe-Ser-Gly-OH (2.18) 
HRMS spectrum 19. Positive ionisation of N-Ac-Gly-Phe-His-Ala-Arg(6-FAM)-Gly-OH (2.19) 
HRMS spectrum 20. Positive ionisation of N-Ac-Gly-Phe-Arg(6-FAM)-Arg(6-FAM)-Gly-OH (2.20) 
HRMS spectrum 21. Positive ionisation of N-Ac-Gly-Phe-Val-Arg(6-FAM)-Gly-Val-Gly-OH (2.21) 
HRMS spectrum 22. Positive ionisation of N-Ac-Gly-Val-Dha-Arg(6-FAM)-Phe-Gly-OH (2.22) 
HRMS spectrum 23. Positive ionisation of N-Ac-Gly-Val-Cys(6-FAM)-Arg-Phe-Gly-OH (2.23) 
HRMS spectrum 24. Positive ionisation of N-Ac-Gly-Lys(6-FAM)-Phe-Arg-Gly-OH (2.24)!
HRMS spectrum 25. Positive ionisation of N-Ac-Gly-Phe-Val-Arg(Biotin)-Gly-Val-Gly-OH (2.25) 
HRMS spectrum 26. Positive ionisation of N-Ac-Gly-Val-Glu-Phe-Arg(Biotin)-Gly-OH (2.26) 
HRMS spectrum 27. Positive ionisation of N-Ac-Gly-Phe-Val-Arg(DA)-Gly-Val-Gly-OH (2.27) 
HRMS spectrum 28. Positive ionisation of N-Ac-Gly-Val-Glu-Phe-Arg(DA)-Gly-OH (2.28) 
HRMS spectrum 29. Positive ionisation of Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg(6-FAM)-Pro-NHEt 
(2.30) 
HRMS spectrum 30. Positive ionisation of N-Ac-Gly-Lys(Boc)-Phe-Arg-Gly-OH (2.31) 
HRMS spectrum 31. Positive ionisation of N-Ac-Gly-Lys(Boc)-Phe-Arg(6-FAM)-Gly-OH (2.32) 
HRMS spectrum 32. Positive ionisation of N-Ac-Gly-Lys-Phe-Arg(6-FAM)-Gly-OH (2.33) 
HRMS spectrum 33. Positive ionisation of MC-LR-(6-FAM) (3.1) 
HRMS spectrum 34. Negative ionisation of MC-LR-(Alexa-430) (3.2) 
HRMS spectrum 35. Negative ionisation of MC-LR-(Alexa-488) (3.3) 
HRMS spectrum 36. Positive ionisation of MC-LR-(Texas-Red) (3.4) 
HRMS spectrum 37. Positive ionisation of MC-LR-(Biotin) (3.5) 
HRMS spectrum 38. Positive ionisation of MC-LR-(DA) (3.6) 
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HRMS spectrum 39. Positive ionisation of CP1020(Benzylamin) (5.1) 
MS spectrum 40. Positive ionisation of CP1020(Coumarin) (5.2) 
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HRMS spectrum 1. Positive ionisation of Bz-Arg(Dansyl)-OMe (2.1) 
 
 
HRMS spectrum 2. Positive ionisation of Bz-Arg(N-succinimid)-OEt (2.2)!
  
 
HRMS spectrum 3. Positive ionisation of Boc-Arg(N-succinimid)-OH (2.3)!
 
 
HRMS spectrum 4. Negative ionisation of N-Ac-Arg(Alexa488)-OH (2.4)!
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HRMS spectrum 5. Positive ionisation of N-Ac-Arg(6-FAM)-OH (2.5)!
 
 
HRMS spectrum 6. Positive ionisation of N-Ac-Arg(coumarin)-OH (2.6)!
 
 
HRMS spectrum 7. Positive ionisation of N-Ac-Gly-Val-Phe-Arg-Gly-OH (2.7) 
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HRMS spectrum 8. Positive ionisation of N-Ac-Gly-Val-Glu-Phe-Arg-Gly-OH (2.8) 
 
HRMS spectrum 9. Positive ionisation of N-Ac-Gly-Lys-Phe-Arg-Gly-OH (2.9) 
 
 
HRMS spectrum 10. Positive ionisation of N-Ac-Gly-Phe-Arg-Arg-Gly-OH (2.10) 
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HRMS spectrum 11. Positive ionisation of N-Ac-Gly-Phe-Val-Arg-Gly-Val-Gly-OH (2.11) 
 
 
HRMS spectrum 12. Positive ionisation of N-Ac-Gly-Val-Arg-Phe-Ser-Gly-OH (2.12) 
 
 
 
 
 
 
 
 
 
 
 
!!
7 Appendix 
!
! !
209 
 
HRMS spectrum 13. Positive ionisation of N-Ac-Gly-Val-Cys-Arg-Phe-Gly-OH (2.13) 
 
 
HRMS spectrum 14. Positive ionisation of N-Ac-Gly-Phe-His-Ala-Arg-Gly-OH (2.14) 
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HRMS spectrum 15. Positive ionisation of N-Ac-Gly-Val-Dha-Arg-Phe-Gly-OH (2.15) 
 
 
HRMS spectrum 16. Positive ionisation of N-Ac-Gly-Val-Phe-Arg(6-FAM)-Gly-OH (2.16) 
 
 
HRMS spectrum 17. Negative ionisation of N-Ac-Gly-Val-Glu-Phe-Arg(6-FAM)-Gly-OH (2.17) 
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HRMS spectrum 18. Negative ionisation of N-Ac-Gly-Val-Arg(6-FAM)-Phe-Ser-Gly-OH (2.18) 
 
 
HRMS spectrum 19. Positive ionisation of N-Ac-Gly-Phe-His-Ala-Arg(6-FAM)-Gly-OH (2.19) 
 
 
HRMS spectrum 20. Positive ionisation of N-Ac-Gly-Phe-Arg(6-FAM)-Arg(6-FAM)-Gly-OH (2.20) 
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HRMS spectrum 21. Positive ionisation of N-Ac-Gly-Phe-Val-Arg(6-FAM)-Gly-Val-Gly-OH (2.21) 
 
 
HRMS spectrum 22. Positive ionisation of N-Ac-Gly-Val-Dha-Arg(6-FAM)-Phe-Gly-OH (2.22) 
 
 
HRMS spectrum 23. Positive ionisation of N-Ac-Gly-Val-Cys(6-FAM)-Arg-Phe-Gly-OH (2.23) 
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HRMS spectrum 24. Positive ionisation of N-Ac-Gly-Lys(6-FAM)-Phe-Arg-Gly-OH (2.24) 
 
 
 
 
HRMS spectrum 25. Positive ionisation of N-Ac-Gly-Phe-Val-Arg(Biotin)-Gly-Val-Gly-OH (2.25) 
 
 
HRMS spectrum 26. Positive ionisation of N-Ac-Gly-Val-Glu-Phe-Arg(Biotin)-Gly-OH (2.26) 
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HRMS spectrum 27. Positive ionisation of N-Ac-Gly-Phe-Val-Arg(DA)-Gly-Val-Gly-OH (2.27) 
 
 
 
HRMS spectrum 28. Positive ionisation of N-Ac-Gly-Val-Glu-Phe-Arg(DA)-Gly-OH (2.28) 
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HRMS spectrum 29. Positive ionisation of Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg(6-FAM)-Pro-NHEt 
(2.30) 
 
 
HRMS spectrum 30. Positive ionisation of N-Ac-Gly-Lys(Boc)-Phe-Arg-Gly-OH (2.31) 
 
 
HRMS spectrum 31. Positive ionisation of N-Ac-Gly-Lys(Boc)-Phe-Arg(6-FAM)-Gly-OH (2.32) 
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HRMS spectrum 32. Positive ionisation of N-Ac-Gly-Lys-Phe-Arg(6-FAM)-Gly-OH (2.33) 
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HRMS spectrum 33. Positive ionisation of MC-LR-(6-FAM) (3.1) 
 
HRMS spectrum 34. Negative ionisation of MC-LR-(Alexa-430) (3.2) 
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HRMS spectrum 35. Negative ionisation of MC-LR-(Alexa-488) (3.3) 
 
HRMS spectrum 36. Positive ionisation of MC-LR-(Texas-Red) (3.4) 
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HRMS spectrum 37. Positive ionisation of MC-LR-(Biotin) (3.5) 
 
 
HRMS spectrum 38. Positive ionisation of MC-LR-(DA) (3.6) 
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HRMS spectrum 39. Positive ionisation of CP1020(Benzylamin) (5.1) 
 
 
MS spectrum 40. Positive ionisation of CP1020(Coumarin) (5.2) 
!
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7.4 MS-MS-Spectra 
 
MS-MS spectrum 1. Positive fragmentation of N-Ac-Gly-Val-Glu-Phe-Arg(6-FAM)-Gly-OH!(2.17) 
MS-MS spectrum 2. Positive fragmentation of N-Ac-Gly-Val-Arg(6-FAM)-Phe-Ser-Gly-OH!(2.18)!
MS-MS spectrum 3. Positive fragmentation of N-Ac-Gly-Phe-His-Ala-Arg(6-FAM)-Gly-OH!(2.19)!
MS-MS spectrum 4. Positive fragmentation of N-Ac-Gly-Val-Cys(6-FAM)-Arg-Phe-Gly-OH!(2.23)!
MS-MS spectrum 5. Positive fragmentation of N-Ac-Gly-Lys(6-FAM)-Phe-Arg-Gly-OH!(2.24) 
MS-MS spectrum 6. Positive fragmentation of Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg(6-FAM)-Pro-NHEt!
(2.30) 
MS-MS spectrum 7. Positive fragmentation of N-Ac-Gly-Lys-Phe-Arg(6-FAM)-Gly-OH!(2.33) 
MS-MS spectrum 8. Negative fragmentation of MC-LR-(6-FAM)!(3.1) 
MS-MS spectrum 9. Negative fragmentation of MC-LR-(Alexa-430) (3.2) 
MS-MS spectrum 10. Positive fragmentation of MC-LR-(Texas-Red)!(3.4) 
MS-MS spectrum 11. Positive fragmentation of CP1020(Benzylamin) (5.1) 
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MS-MS spectrum 1. Positive fragmentation of N-Ac-Gly-Val-Glu-Phe-Arg(6-FAM)-Gly-OH!(2.17) 
 
Mass  Fragment 
737.6  +H3N-Phe-Arg(6-FAM)-Gly-OH 
The ion at m/z = 737.6 supports the assignment of the labelled Arg residue. 
 
MS-MS spectrum 2. Positive fragmentation of N-Ac-Gly-Val-Arg(6-FAM)-Phe-Ser-Gly-OH!(2.18)!
 
Mass  Fragment 
713.6  N-Ac-Gly-Val-Arg(6-FAM)- O+ 
1005.8 N-Ac-Gly-Val-Arg(6-FAM)-Phe-Ser-Gly-O+ 
The ion at m/z = 713.6 supports the assignment of the labelled Arg residue. 
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MS-MS spectrum 3. Positive fragmentation of N-Ac-Gly-Phe-His-Ala-Arg(6-FAM)-Gly-OH!(2.19)!
 
Mass  Fragment 
401.1   N-Ac-Gly-Phe-His-NH3+ 
455.2  N-Ac-Gly-Phe-His-Ala-O+ 
590.2  +H3N-Arg(6-FAM)-Gly-OH 
661.2  +H3N-Ala-Arg(6-FAM)-Gly-OH 
798.3  +H3N -His-Ala-Arg(6-FAM)-Gly-OH 
969.3  N-Ac-Gly-Phe-His-Ala-Arg(6-FAM)-O+ 
1027.3 N-Ac-Gly-Phe-His-Ala-Arg(6-FAM)-Gly-O+ 
The ion at m/z = 590.2 supports the assignment of the labelled Arg residue. 
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MS-MS spectrum 4. Positive fragmentation of N-Ac-Gly-Val-Cys(6-FAM)-Arg-Phe-Gly-OH!(2.23)!
 
Mass  Fragment 
660.2  N-Ac-Gly-Val-Cys(6-FAM)-O+ 
677.2  N-Ac-Gly-Val-Cys(6-FAM)-NH3+ 
816.3  N-Ac-Gly-Val-Cys(6-FAM)-Arg-O+ 
963.4  N-Ac-Gly-Val-Cys(6-FAM)-Arg-Phe-O+ 
The ion at m/z = 963.4 supports the assignment of the labelling of the unfavoured 
Cys residue. 
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MS-MS spectrum 5. Positive fragmentation of N-Ac-Gly-Lys(6-FAM)-Phe-Arg-Gly-OH!(2.24) 
 
Mass  Fragment 
586.1  N-Ac-Gly-Lys(6-FAM)-O+ 
733.2  N-Ac-Gly-Lys(6-FAM)-Phe-O+ 
The ion at m/z = 586.1 and 733.2 supports the assignment of the labelling of the 
unfavoured Lys residue. 
 
MS-MS spectrum 6. Positive fragmentation of Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg(6-FAM)-Pro-NHEt!
(2.30) 
 
Mass  Fragment 
640.7  +Arg(6-FAM)-Pro-NHEt 
The ion at m/z = 640.7 supports the assignment of the labelled Arg residue. 
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MS-MS spectrum 7. Positive fragmentation of N-Ac-Gly-Lys-Phe-Arg(6-FAM)-Gly-OH!(2.33) 
 
Mass  Fragment 
737.2  +NH3-Phe.Arg(6-FAM)-Gly-OH 
889.3  N-Ac-Gly-Lys-Phe-Arg(6-FAM)-O+ 
The ion at m/z = 737.2 supports the assignment of the labelled Arg residue. 
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The ions with 135 mass units less, result from the cleavage of the Adda side chain, 
between the methylester and the methyl group.[1]  
 
MS-MS spectrum 8. Negative fragmentation of MC-LR-(6-FAM)!(3.1) 
!
Mass  Fragment 
1334.2 - H2O 
1317.1 - H2O, NH3 
1299.1 - Dha 
1223.1 - Leu,H2O 
933.9  MeAsp-Arg-(6-FAM)-Glu-(-135,-H2O) 
916.8  MeAsp-Arg-(6-FAM)-Glu-(-135,-H2O,-NH3) 
 
Unfortunately no fragment can entirely exclude the attachment of the fluorophore to 
the Glu or MeAsp side chain. 
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MS-MS spectrum 9. Negative fragmentation of MC-LR-(Alexa-430) (3.2) 
 
Mass  Fragment 
1461.3 - H2O 
1444.2 - H2O, NH3 
993.8  Adda-Arg-(Alexa-430)-MeAsp-(-135) 
976.2  Adda-Arg-(Alexa-430)-MeAsp-(-135,-NH3) 
933.8  Arg-(Alexa-430)-Glu-(-135,-NH3) 
526.3  MeAsp-Leu-Ala-Mdha-Glu 
 
The ion at m/z = 526.3 supports the assignment of the labelled Arg residue. 
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MS-MS spectrum 10. Positive fragmentation of MC-LR-(Texas-Red)!(3.4) 
 
 
Mass  Fragment 
1679.5 - H2O 
1301.1 Adda-Arg-(Texas-Red)-Glu-O+ 
875.7  Arg-(Texas-Red)-NH3+ 
702.5  Adda-Glu-Mdha-Ala-Leu-MeAsp(-135,-NH3) 
607.4  Adda-Glu-Mdha-Ala-Leu-CH3+(-135) 
 
The ion at m/z = 875.7 and 702.5 supports the assignment of the labelled Arg 
residue. 
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MS-MS spectrum 11. Positive fragmentation of CP1020(Benzylamin) (5.1) 
 
 
Mass  Fragment 
1004.0 - Bn 
776.8  -AhpBn 
467.5  Hex-Glu-Didehydrobutyrate-Arg+ 
420.4  Phe-Tyr-Val-OH+ 
 
The ion at m/z = 1004 supports the attachment of the amine at the carboxylic acid. !!
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